Patent Publication Number: US-2010120747-A1

Title: Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity

Description:
FIELD OF THE INVENTION 
     The present invention relates to an active substance combination comprising at least one compound with 5-HT 6  receptor affinity, and at least one cholinesterase inhibitor, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. 
     BACKGROUND OF THE INVENTION 
     Cognitive and/or degenerative brain disorders are characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profound mental deterioration and ultimately death. In an example of such disorders, Alzheimer&#39;s disease is a common cause of progressive mental failure (dementia) in aged humans and is believed to represent the fourth most common medical cause of death in the United States. In particular, Alzheimer&#39;s disease is associated with degeneration of cholinergic neurons in the basal forebrain that play a fundamental role in cognitive functions, including memory. Cognitive and/or degenerative brain disorders have been observed in varied races and ethnic groups world-wide and presents a major public health problem. These diseases are currently estimated to affect about two to three million individuals in the United States alone and the occurrence will increase world-wide as the human life span increases. 
     Cognitive and/or degenerative brain disorders are incurable with presently used medications, however, the symptoms of these disorders can be alleviated by using compounds useful for treating cognitive disorders, in particular for treating Alzheimer&#39;s disease, such as donepezil, rivastigmine, galantamine and phenserine all of which act as acetylcholinesterase inhibitors. 
     All acetylcholinesterase inhibitors have serious drawbacks in that they produce undesirable side affects caused by their activity as acetylcholinesterase inhibitors. These undesirable side effects are related to their toxicity caused by their suppression of acetylcholinesterase. Due to the fact that acetylcholinesterase inhibitors, which are administered chronically, have a low therapeutic ratio (i.e. the ratio between toxicity and therapeutic effect) they produce a number of pathologic conditions associated with cholinergic under activity. Therefore due to the chronic nature of treatment for cognitive disorders it has long been desired to provide a medicament which is effective and does not produce the toxic side effects inherent in the use of acetylcholinesterase inhibitors and does not present undesired side effects such as nausea and vomiting and, thus, can be administered for long periods. 
     BRIEF DESCRIPTION OF THE INVENTION 
     It was therefore an object of the present invention to provide a medicament suitable for the prophylaxis and/or treatment of disorders related to acetylcholinesterase, and to 5-HT 6  receptors, which preferably does not show the undesired side effects of the conventional compounds which act as cholinesterase inhibitors, or at least less frequent and/or less pronounced. 
     In particular, it was an object of the present invention to provide a medicament suitable for the prophylaxis and/or treatment of cognitive disorders, which preferably does not show the undesired side effects of the conventional medicaments for the prophylaxis and/or treatment of cognitive disorders, or at least less frequent and/or less pronounced. 
     Said object has been achieved by providing an active substance combination comprising 
     (A) at least one compound with 5-HT 6  receptor affinity, and 
     (B) at least one cholinesterase inhibitor. 
     whereby an active substance combination comprising as component (A) the 5-HT6 antagonist SB271046 and as component (B) the cholinesterase inhibitor donepezil hydrochloride is excluded. 
     Donepezil hydrochloride is sold under the brand name Aricept® as a medication to treat Alzheimer&#39;s disease. The respective compound donepezil hydrochloride has the code names BNAG and E-2020, respectively. 
     Another object of the present invention relates to an active substance combination as defined above for its use as a medicament. 
     A third object of the invention refers to the use of the combination as defined above for the manufacture of a medicament for simultaneous acetylcholinesterase inhibition and 5-HT6-receptor regulation. 
     Even another object of the invention relates to the use of the combination as defined above for the manufacture of a medicament for regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin- dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome, for prophylaxis and/or treatment of Metabolic Syndrome, Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, such as Alzheimer&#39;s, Parkinson&#39;s and/or Huntington&#39;s Disease, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatory diseases, immunologic diseases or for improvement of cognition. 
     Finally, another object refers to a pharmaceutical formulation, characterized in that it comprises an active substance combination as defined above and optionally one or more pharmacologically acceptable adjuvants. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     It has surprisingly been found that the compounds with 5-HT 6  receptor affinity and the compounds which act as cholinesterase inhibitors show a synergistic effect in their pharmacological activities. Consequently, the dose of the corresponding compounds may be reduced in comparison to the dose necessary for an individual administration of said compounds. In particular, the combination of an amount of compound with 5-HT 6  receptor affinity and an amount of cholinesterase inhibitor which both basically do not show any pharmacological activity in these amounts leads to an active substance combination of these compounds which shows a pharmacological activity when these amounts are administered in combination. 
     According to the invention it has also been found that the action of a acetylcholinesterase inhibitor potentiates the action of the compound with 5-HT 6  receptor affinity, so the combination of a cholinesterase inhibitor and a compound with 5-HT 6  receptor affinity for use in the treatment of disorders that are related to acetylcholinesterase, and to 5-HT 6  receptors may result in a faster onset of action and an increased success rate. The invention therefore resides in the combined action of a cholinesterase inhibitor and a compound with 5-HT 6  receptor affinity, or the dual action of a substance possessing both cholinesterase inhibitor activity and 5-HT 6  receptor affinity, for the treatment of disorders that are related to acetylcholinesterase, and to 5-HT 6  receptors. 
     Preferably the compounds which are present as component (A) have selective affinity for 5-HT 6  receptors. Thus, these compounds have a higher affinity for the 5-HT 6  receptor than for other 5-HT receptors subtypes and preferably do not substantially bind to other 5-HT receptor subtypes such as 5-HT 1  receptors (e.g. 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , 5-HT 1F ), 5-HT 2B , 5-HT 2C , 5-HT 2a  and 5-HT 7 . 
     More preferably the compounds which are present as component (A) will exhibit an affinity (pKi) for the 5-HT 6  receptor with a value of greater than or equal to about 6, preferably with a value of greater than or equal to about 8, more preferably with a value of greater than or equal to about 9, which is at least 20-fold greater than, preferably at least 30-fold greater than its pKi for the 5-HT 2c  receptor. Assays that may be used for determining the affinity and selectivity of a 5-HT 6  receptor antagonist and/or a 5-HT 2  receptor antagonist are well known in the art and are also provided in the examples below. 
     Preferably the compound present as component (A) shows a K i  value for binding to the 5-HT 6 -receptor of below or equal to 1 μM, preferably below or equal to 500 nM, more preferably below or equal to 100 nM, even more preferably below or equal to 50 nM, still even more preferably below or equal to 25 nM. 
     Preferably cell membranes of HEK-293 cells expressing the 5HT 6 -human recombinant receptor were used for determining the K. In said membranes the receptor concentration was 2.18 pmol/mg protein and the protein concentration is 9.17 mg/ml. The experimental protocol followed the method of B. L. Roth et al. [B. L. Roth, S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Y. Shen, H. Y. Meltzer, D. R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytryptamine-7 Receptors. The Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 1403] which is hereby incorporated by reference and forms part of the disclosure. The exact experimental protocol is also outlined below (see Pharmacological Methods). 
     In a particular embodiment of the invention, the component (A) exhibit an affinity for the 5-HT 6  receptor acting as agonist thereof. In another particular embodiment, the component (A) exhibit an affinity for the 5-HT 6  receptor acting as antagonist thereof. In still another particular embodiment, the component (A) exhibit an affinity for the 5-HT 6  receptor acting as inverse agonist thereof. 
     Preferably the compound with 5-HT 6  receptor affinity acts as agonist or inverse agonist of the 5-HT 6  receptor, more preferably the compound with 5-HT 6  receptor affinity acts as agonist of the 5-HT 6  receptor. More preferably the compound with 5-HT 6  receptor affinity acts as selective agonist or selective inverse agonist of the 5-HT 6  receptor, more preferably the compound with 5-HT 6  receptor affinity acts as selective agonist of the 5-HT 6  receptor. 
     It is possible to classify a compound with 5-HT6 receptor affinity as agonist, inverse agonist or antagonist according to the reference of S. M. Stahl, Essential Psychopharmacology, Neuroscientific basis and practical applications, Ed. Cambridge, 1996, Chapter 3. The respective part of the literature is hereby incorporated by reference and forms part of the disclosure. 
     An “Agonist” is defined as a compound that binds to a receptor and has an intrinsic effect, and thus, increases the basal activity of a receptor when it contacts the receptor. 
     An “antagonist” is defined as a compound that competes with an agonist or inverse agonist for binding to a receptor, thereby blocking the action of an agonist or inverse agonist on the receptor. However, an antagonist (also known as a “neutral” antagonist) has no effect on constitutive receptor activity. 
     An “inverse agonist” is defined as a compound that produces an effect opposite to that of the agonist by occupying the same receptor and, thus, decreases the basal activity of a receptor (i.e., signalling mediated by the receptor). Such compounds are also known as negative antagonists. An inverse agonist is a ligand for a receptor that causes the receptor to adopt an inactive state relative to a basal state occurring in the absence of any ligand. Thus, while an antagonist can inhibit the activity of an agonist, an inverse agonist is a ligand that can alter the conformation of the receptor in the absence of an agonist. 
     According to the present invention, the term “cholinesterase inhibitor” denotes acetylcholinesterase inhibitors as well as butyrylcholinesterase inhibitors. 
     The compound present as component (B) shows an IC 50  for the inhibition of acetylcholinesterase in erythrocytes below or equal to 1 μM, preferably below or equal to 500 nM, more preferably below or equal to 300 nM, even more preferably below or equal to 200 nM, still even more preferably below or equal to 100 nM. 
     Assays that may be used for determining the inhibition of acetylcholinesterase in erythrocytes are well known in the art and are also provided in the following references: J. Med. Chem. 2002, 45, 3684; J. Med. Chem. 2001, 44, 4733 and J. Med. Chem. 2005, 48, 1701. The respective parts of the literature are hereby incorporated by reference and form part of the disclosure. 
     Preferably the cholinesterase inhibitor according to the present invention is selected from the group consisting of reversible cholinesterase inhibitors and pseudo-reversible cholinesterase inhibitors. 
     The terms “cholinesterase inhibitor” and “acetylcholinesterase inhibitor” interchangeably refer to a pharmaceutical compound that inhibits the activity of the enzyme acetylcholinesterase (AChE). Cholinesterase inhibitors are generally classified as “reversible,” “pseudo-irreversible” or “slow reversible,” and “irreversible.” “Reversible” cholinesterase inhibitors typically are non-covalent inhibitors. “Pseudo-irreversible,” “pseudo-reversible” or “slow reversible” cholinesterase inhibitors react covalently or noncovalently with AChE with high affinity. Pseudo-irreversible cholinesterase inhibitors typically, but nonexclusively, have a carbamoyl ester linkage and are hydrolysed by AChE, but much more slowly than acetylcholine. Attack by the active centre serine of AChE gives rise to a carbamoylated AChE. The duration of inhibition by the carbamoylating acetylcholinesterase inhibitors can be about 3 to 4 hours. The half-life of such carbamoylating agents, for example, physostigmine, neostigmine, and pyridostigmine, can be about 1 to 2 hours. The distinction between “pseudo-irreversible” and “reversible” cholinesterase inhibitors generally reflects quantitative differences in rates of deacylation of the acyl enzyme. With “pseudo-irreversible” cholinesterase inhibitors, the half-life for hydrolysis of the dimethylcarbamoyl enzyme is about 15 to 30 minutes. “Irreversible” cholinesterase inhibitors are usually organophophorus compounds. With “irreversible” cholinesterase inhibitors, the active enzyme can spontaneously regenerate after several hours or so slowly that the return of AChE activity depends on the synthesis of new enzyme. Acetylcholinesterase inhibitors are well known and discussed in detail in, for example, Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, Chapter 8, 10.sup.th Ed., Hardman, Limbird and Goodman-Gilman, Eds., McGraw-Hill (2001), hereby incorporated herein by reference. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of the benzoxazinone-derived sulfonamide compounds of general formula (Ia) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1a , R 2a , R 3a  and R 4a , independently of one another, each represent a hydrogen atom; halogen; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ringsystem; nitro; cyano; —O—R 10a ; —O—(C═O)—R 11a ; —(C═O)—OR 11a ; —SR 12a ; —SOR 12a ; —SO 2 R 12a; , —NH—SO 2 R 12a ; —SO 2 NH 2  or —NR 13a R 14a ; 
     R 5a  represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical; 
     R 6a , R 7a , R 8a , R 9a , independently of one another, each represent a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical; a cyano group or a —C(═O)—OR 15a  moiety; 
     W a  represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene or alkenylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     a —NR 16a R 17a  moiety, or 
     a —C(═O)—R 18a  moiety; 
     R 10a  represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 11a  represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 12a  represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 13a  and R 14a , independently of one another, each represent a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     or R 13a  and R 14a  together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which is unsubstituted or at least mono-substituted and/or which may contain at least one further heteroatom as a ring member; 
     R 15a  represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 16a  represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 17a  represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical, and 
     R 18a  represents an unsubstituted or at least mono-substituted aryl radical; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively. 
     Preferred compounds of general formula (Ia) are those, wherein 
     R 1a , R 2a , R 3a  and R 4a , independently of one another, each represent a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group or a methoxy group; 
     R 5a  represents a hydrogen atom; 
     R 6a , R 7a , R 8a  and R 9a  each represent a hydrogen atom; 
     W a  represents 
     an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; isobutyl and tert-butyl; vinyl (CH 2 ═CH—); —N(CH 3 ) 2 ; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-isobutyl-phenyl; 3-isobutyl-phenyl; 4-isobutyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C═O)—O—CH 3 -phenyl; 3-(C═O)—O—CH 3 -phenyl; 4-(C═O)—O—CH 3 -phenyl; 2-(CH 2 )—(CH 2 )—(C═O)—O—CH 3 -phenyl; 3-(CH 2 )—(CH 2 )—(C═O)—O—CH 3 -phenyl; 4-(CH 2 )—(CH 2 )—(C═O)—O—CH 3 -phenyl; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl(biphenyl-2-yl); 3-phenyl-phenyl(biphenyl-3-yl); 4-phenyl-phenyl(biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-d ichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)—(C═O)—CH 3 -phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     whereby in each case X denotes the position by which the respective substituent W a  is bonded to the —SO 2  group of formula (Ia); 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively. 
     Particularly preferred compounds of general formula (Ia) are those selected from the group consisting of: 
     1a 1-[1-(Naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     1b 1-[1-(Naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     2 1-[1-(Toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     3 1-(1-Phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     4 1-(1-Benzenesulfonyl-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     5 6-Chloro-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     6 6-Chloro-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     7 6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     8 6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     9 6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     10 1-[1-(Thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     11 1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     12 2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     13 1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     14 1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     15 1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     16 8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     17 1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     18 2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     19 1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     20 1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     21 8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     22 4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide 
     23 2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester 
     24 1-[1-(3-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     25 2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester 
     26 8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     27 1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     28 2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     29 6-Chloro-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     30 2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester 
     31 6-Chloro-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     32 6-Chloro-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     33 1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     34 1-{1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     35 1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     36 8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     37 8-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     38 1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     39 6-Chloro-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     40 1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     41 1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     42 1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     43 1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     44 6-Chloro-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     45 6-Chloro-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     46 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     47 8-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     48 8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     49 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     50 8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     51 6-Chloro-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     52 1-(1-Ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     53 1-[1-(Propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     54 1-[1-(Propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     55 6-Chloro-1-(1-ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     56 6-Chloro-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     57 6-Chloro-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     58 6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     59 1-[1-(4-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     60 6-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     61 6-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     62 6-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     63 1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     64 6-Methyl-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     65 6-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     66 1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     67 6-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     68 1-(1-Benzenesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     69 1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     70 1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     71 1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     72 1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     73 6-Chloro-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     74 6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     75 1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     76 1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     77 6-Chloro-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     78 1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     79 1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     80 1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     81 1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     82 1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     83 6-Chloro-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     84 1-[1-(2,3-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     85 1-[1-(2,4,5-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     86 8-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     87 6-Chloro-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     88 6-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     89 1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     90 1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     91 1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     92 1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     93 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     94 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     95 6-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     96 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     97 1-(1-Pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     98 8-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     99 6-Chloro-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     100 6-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     101 1-{1-[2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     102 8-Methyl-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     103 6-Chloro-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     104 6-Methyl-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     105 1-[1-(2-Methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     106 8-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     107 6-Chloro-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     108 6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     109 1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     110 1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     111 1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     112 1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     113 1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     114 1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     115 6-Chloro-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     116 1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     117 1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     118 1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     119 1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     120 6-Chloro-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     121 1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     122 1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     123 1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     124 6-Chloro-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     125 1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     126 1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     127 6-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     128 6-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     129 1-[1-(4-Trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     130 1-[1-(2-Nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     131 1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     132 1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     133 1-[1-(2,4,6-Trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     134 1-[1-(2-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     135 8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     136 8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     137 1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     138 1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     139 8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     140 8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     141 1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     142 1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     143 1-[1-(3-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     144 1-{1-[1-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     145 1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     146 1-[1-(2-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     147 8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     148 1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     149 1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     150 1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     151 1-{1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     152 6-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     153 1-[1-(Toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     154 1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     155 1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     156 1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     157 1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     158 1-(1-Pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     159 8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     160 1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one 
     161 1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     162 1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     163 1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     164 8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     165 6-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     166 1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     167 1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     168 1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     169 1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     170 6-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     171 6-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     172 6-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     173 1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     174 1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     175 6-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     176 6-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     177 1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     178 6-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     179 1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     180 1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     181 6-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     182 2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]benzoic acid methyl ester 
     183 6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     184 6-Chloro-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     185 6-Chloro-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     186 1-{1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     187 6-Chloro-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     188 6-Chloro-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     189 6-Chloro-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     190 6-Chloro-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     191 6-Chloro-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     192 6-Chloro-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     193 6-Chloro-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     194 6-Chloro-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     195 6-Chloro-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     196 6-Chloro-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     197 6-Chloro-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     198 6-Chloro-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     199 6-Chloro-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     200 6-Chloro-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     201 6-Chloro-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     202 1-[1-(2-Oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     203 1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     204 1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     205 1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     206 1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     207 1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     208 8-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     209 1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     210 1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     211 1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     212 1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     213 1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     214 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     215 6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     216 1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     217 6-Chloro-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     218 6-Chloro-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     219 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     220 2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     221 1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     222 1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     223 1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     224 1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     225 1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     226 6-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     227 1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     228 1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     229 1-[1-(1-Methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     230 1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     231 1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     232 1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     233 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     234 1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     235 1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     236 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     237 6-Chloro-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     238 6-Chloro-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     239 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     240 1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     241 1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     242 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     243 1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     244 1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     245 3-{4-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester 
     246 1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     247 1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     248 1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     249 3-{4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester 
     250 1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     251 1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     252 1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     253 3-{4-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester 
     254 1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     255 6-Chloro-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     256 6-Chloro-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     257 3-{4-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester 
     258 6-Chloro-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     259 6-Chloro-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     260 1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     261 8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     262 1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     263 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     264 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     265 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     266 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     267 1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     268 1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     269 6-Chloro-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     270 1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     271 1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     272 1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     273 6-Chloro-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     274 1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     275 1-[1-(2,4,5-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     276 8-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     277 6-Chloro-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     278 6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     279 1-[1-(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     280 1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     281 1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     282 6-Chloro-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     283 1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     284 1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     285 1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     286 6-Chloro-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     287 1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     288 1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     289 1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     290 6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     291 1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     292 6-Chloro-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     293 6-Bromo-1-[1-(4-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     294 6-Bromo-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     295 6-Bromo-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     296 6-Bromo-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     297 6-Bromo-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     298 6-Bromo-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     299 6-Bromo-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     300 6-Bromo-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     301 6-Bromo-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     302 1-(1-Benzenesulfonyl-piperidin-4-yl)-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     303 6-Bromo-1-{1-[1-(4-bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     304 6-Bromo-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     305 6-Bromo-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     306 6-Bromo-1-[1-(4-bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     307 6-Bromo-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     308 6-Bromo-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     309 6-Bromo-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     310 6-Bromo-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     311 6-Bromo-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     312 6-Bromo-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     313 6-Bromo-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     314 6-Bromo-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     315 6-Bromo-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     316 6-Bromo-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     317 6-Bromo-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     318 6-Bromo-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     319 6-Bromo-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     320 6-Bromo-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     321 6-Bromo-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     322 6-Bromo-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     323 1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     324 6-Bromo-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     325 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     326 6-Bromo-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     327 6-Bromo-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     328 6-Bromo-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     329 6-Bromo-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     330 6-Bromo-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     331 6-Bromo-1-[1-(5-bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     332 6-Bromo-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     333 6-Bromo-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     334 6-Bromo-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     335 6-Bromo-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     336 6-Bromo-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     337 6-Bromo-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     338 6-Bromo-1-[1-(2-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     339 6-Bromo-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     340 1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     341 1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     342 6-Chloro-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     343 1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     344 6-Bromo-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     345 6-Chloro-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     346 6-Bromo-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     347 2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     348 6-Bromo-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     349 2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester 
     350 6-Bromo-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     351 6-Bromo-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     352 6-Bromo-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     353 6-Bromo-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     354 6-Bromo-1-[1-(5-bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     355 6-Bromo-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     356 6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     357 6-Bromo-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     358 6-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     359 6-Bromo-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     360 6-Bromo-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     361 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     362 6-Bromo-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     363 6-Bromo-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     364 3-{4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester 
     365 6-Bromo-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     366 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     367 6-Bromo-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     368 6-Bromo-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     369 6-Bromo-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     370 6-Bromo-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     371 6-Bromo-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     372 6-Bromo-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     373 6-Bromo-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     374 N-{4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-2-chloro-phenyl)-acetamide 
     375 1-[1-(2,3,4-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     376 8-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     377 6-Chloro-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     378 6-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     379 N-{2-Chloro-4-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-acetamide 
     380 1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     381 1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     382 6-Chloro-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     383 1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     384 6-Bromo-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     385 N-{2-Chloro-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-acetamide 
     386 1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     387 1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     388 6-Chloro-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     389 1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     390 6-Bromo-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     391 N-{2-Chloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-acetamide 
     392 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     393 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     394 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     395 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     396 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     397 N-{2-Chloro-4-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-acetamide 
     398 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     399 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     400 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     401 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     402 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     403 1-(1-Ethanesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     404 1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     405 1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     406 6-Chloro-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     407 1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     408 6-Bromo-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     409 8-Methyl-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     410 1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     411 1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     412 6-Chloro-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     413 1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     414 6-Bromo-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     415 8-Methyl-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     416 1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     417 1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     418 6-Chloro-1-[1-(2-chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     419 1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     420 1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     421 8-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     422 1-[1-(2,3,4-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     423 8-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     424 6-Chloro-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     425 6-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     426 6-Bromo-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     427 1-[1-(2,3,5,6-Tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     428 1-[1-(Thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     429 8-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     430 6-Chloro-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     431 6-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     432 6-Bromo-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     433 6-Chloro-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     434 1-[1-(2,4,6-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     435 8-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     436 6-Chloro-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     437 6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     438 6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     439 6-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     440 1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     441 1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-di hydro-benzo[d][1,3]oxazin-2-one 
     442 1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     443 6-Bromo-1-[1-(2-bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     444 6-Bromo-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     445 1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     446 1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     447 1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     448 1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     449 6-Bromo-1-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     450 1-[1-(4-Phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     451 1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     452 1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     453 1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     454 1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     455 6-Bromo-1-[1-(3-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     456 8-Methyl-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     457 1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     458 1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     459 1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     460 1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     461 6-Bromo-1-[1-(4-tert-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     462 6-Chloro-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     463 1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     464 1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     465 6-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     466 1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     467 6-Bromo-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     468 8-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     469 6-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     470 6-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     471 6-Bromo-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     472 1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     473 6-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     474 1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     475 6-Bromo-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     476 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     477 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     478 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     479 6-Bromo-1-[1-(4-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     480 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     481 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     482 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     483 6-Bromo-1-[1-(4-bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     484 1-{1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     485 6-Chloro-1-{1-[1-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     486 1-{1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     487 6-Bromo-1-{1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     488 1-(1-Ethenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     489 3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     490 3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     491 3-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     492 1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     493 6-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     494 1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     495 6-Bromo-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     496 N-{4-Methyl-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl}-acetamide 
     497 N-{5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide 
     498 N-{4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl}-acetamide 
     499 N-{5-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide 
     500 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     501 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     502 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     503 6-Bromo-1-[1-(2-bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     504 1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     505 6-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     506 1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     507 6-Bromo-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     508 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     509 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     510 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     511 6-Bromo-1-[1-(4-bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     512 1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     513 1-[1-(4-Propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     514 1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     515 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     516 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     517 1-{1-[1-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     518 N-{4-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl}-acetamide 
     519 1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     520 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     521 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     522 1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     523 1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     524 6-Fluoro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     525 6-Fluoro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     526 1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     527 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     528 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     529 1-{1-[1-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     530 N-{5-[4-(6-Fluoro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide 
     531 1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     532 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     533 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     534 1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     535 6-Fluoro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     536 6-Fluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     537 1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     538 6-Fluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     539 6-Fluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     540 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     541 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     542 8-Methoxy-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     543 1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     544 8-Methoxy-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     545 8-Methoxy-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     546 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     547 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     548 5-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     549 5-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     550 5-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     551 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     552 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     553 5-Chloro-1-{1-[1-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     554 N-{5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide 
     555 5-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     556 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     557 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     558 5-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     559 5-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     560 1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     561 1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     562 1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     563 1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     564 1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     565 1-{1-[1-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl}-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     566 N-{5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide 
     567 1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     568 1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     569 1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     570 1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     571 1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride 
     572 1-[1-(4-Methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     573 6-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     574 6-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     575 8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     576 6-Fluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     577 8-Methoxy-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     578 5-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     579 5-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     580 5-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     581 5-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     582 5-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     583 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     584 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     585 6-Bromo-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     586 2-Chloro-4-fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     587 2-Chloro-5-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid 
     588 2-Chloro-4-fluoro-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     589 2-Chloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     590 2-Chloro-4-fluoro-5-[4-(8-methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     591 2-Chloro-5-[4-(5-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-pi peridine-1-sulfonyl]-4-fluoro-benzoic acid 
     592 3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     593 3-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     594 3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     595 1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride 
     596 6-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride 
     597 41-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride 
     598 6,7-Difluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     599 1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     600 6,7-Difluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     601 6,7-Difluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     602 1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     603 1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     604 1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     605 1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     606 1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     607 1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     608 1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     609 6,7-Difluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     610 1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     611 1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     612 1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     613 1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     614 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     615 1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     616 1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     617 1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     618 1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     619 1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     620 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     621 1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     622 5-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     623 5-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     624 5-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     625 5-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     626 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     627 5-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     628 1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     629 1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     630 1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     631 1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     632 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     633 1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     634 6-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     635 6-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     636 6-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     637 6-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     638 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     639 6-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     640 1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     641 1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     642 1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     643 1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     644 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     645 1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     646 1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     647 6,7-Difluoro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     648 1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     649 1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     650 1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     651 6,7-Difluoro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     652 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     653 1-[1-(5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     654 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     655 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     656 8-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     657 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     658 6-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     659 6-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     660 6-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     661 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     662 8-Methoxy-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     663 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     664 5-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     665 5-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     666 5-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     667 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     668 6-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     669 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     670 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     671 6-Fluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     672 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     673 1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     674 6,7-Difluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     675 1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     676 1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     677 1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     678 N-{5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-acetamide 
     679 1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     680 1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     681 N-{5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-acetamide 
     682 5-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     683 5-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     684 N-{5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-acetamide 
     685 1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     686 1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     687 N-{5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-acetamide 
     688 2,5-Dimethyl-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester 
     689 8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     690 1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     691 8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     692 1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     693 2 ,5-Dimethyl-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester 
     694 1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     695 1-[1-(2-Oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     696 1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     697 2-Fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     698 2-Fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid 
     699 1-[1-(2-Oxo-2,3-dihydro-benzoth iazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     700 1-[1-(5-Pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     701 3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     702 3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-pi peridine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester 
     703 1-{5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-pyrrolidine-2,5-dione 
     704 1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     705 1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     706 8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     707 3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     708 3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester 
     709 1-{5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-pyrrolidine-2,5-dione 
     710 1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     711 1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     712 5-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     713 3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     714 3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester 
     715 1-{5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-pyrrolidine-2,5-dione 
     716 5-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     717 5-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     718 6-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     719 3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     720 3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester 
     721 1-{5-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-pyrrolidine-2,5-dione 
     722 1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     723 1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     724 6-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     725 3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile 
     726 3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester 
     727 1-{5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl}-pyrrolidine-2,5-dione 
     728 6-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     729 6-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     730 1-[1-(5-Methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     731 1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     732 1-[1-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     733 1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     734 1-[1-(1,3,5-Trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     735 1-[1-(3-Methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     736 8-Methyl-1-[1-(5-methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     737 1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     738 8-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     739 1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     740 8-Methyl-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     741 8-Methyl-1-[1-(3-methyl-2-oxo-2,3-di hydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     742 8-Methoxy-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     743 8-Methoxy-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     744 1-[1-(Benzo[d]isoxazol-3-ylmethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     745 1-[1-(2,2,4,6,7-Pentamethyl-2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     746 6-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1H-pyrimidine-2,4-dione 
     747 1-[1-(3-Methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     748 1-[1-(2,2,5,7,8-Pentamethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     749 1,4-Dimethyl-644-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,4-dihydro-quinoxaline-2,3-dione 
     750 1-[1-(1H-Imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     751 1-[1-(2-Oxo-1,2,3,4-tetrahydro-quinoline-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     752 7-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione 
     753 8-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     754 6-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     755 5-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     756 8-Methoxy-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     757 1-[1-(Pyridine-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     758 1-[1-(6,7-Dihydroxy-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     759 Acetic acid 3-acetoxy-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-2-ylester 
     760 1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     761 1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     762 1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     763 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     764 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     765 1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     766 5-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     767 1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     768 5-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     769 6-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     770 1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     771 1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     772 6-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     773 1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     774 1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     775 6-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     776 6-Fluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     777 6,7-Difluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     778 6-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     779 6-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     780 6-Fluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     781 6,7-Difluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     782 5-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     783 6-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     784 6-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     785 6-Fluoro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     786 8-Methoxy-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazi ne-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
     787 5-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-on ; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively. 
     The compounds of general formula (Ia) can be prepared according to the disclosure of WO 2005/014045. The respective part of the literature is hereby incorporated by reference and forms part of the present disclosure. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of indole-derived sulfonamide compounds of general formula (Ib) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1b  K represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, 
     which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; a —(CH 2 ) mb —NR 13b R 14b  moiety with mb=0, 1, 2, 3, 4 or 5; a —C(═O)—R 8b  moiety; a —S(═O) 2 —R 9b  moiety; or a —S(═O) 2 —C(H)A b B b  moiety; 
     R 2b  K represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —O—R 10b ; —S—R 11b ; —C(═O)—OR 12b ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a chain member containing aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3b  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10b ; —S—R 11b ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; a —CH(OC 2 H 5 )—CH 2 —NR 13b R 14b  moiety or a —(CH 2 ) nb —NR 13b R 14b  moiety with nb=0, 1, 2, 3, 4 or 5; a —S(═O) 2 —R 9b  moiety; a —S(═O) 2 —C(H)A b B b  moiety; or a —C(═O)—(CH 2 ) pb —C(═O)—N-D b E b  moiety with pb=0, 1, 2, 3, 4 or 5; 
     R 4b , R 5b , R 6b  and R 7b , independently of one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O) 2 —OH; —C(═O)—NH 2 ; —S(═O) 2 —NH 2 ; —C(═O)—R 8b ; —S(═O) 2 —R 9b ; —O—R 19b ; —S—R 11b ; —C(═O)—OR 12b ; —N(R 15b )—S(═O) 2 —R 16b ; —NH—R 17b ; —NR 18b R 19b ; —C(═O)—NHR 20b , —C(═O)—NR 21b R 22b ; —S(═O) 2 —NHR 23b ; —S(═O) 2 —NR 24b R 25b ; —O—C(═O)—R 26b ; —NH—C(═O)—R 27b ; —NR 28b —C(═O)—R 29b ; NH—C(═O)—O—R 30b ; NR 31b —C(═O)—O—R 32b ; —S(═O) 2 —O—R 33b ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     with the proviso that at least one of the substituents R b , R 5b , R 6b  and R 7b  represents a —N(R 15b )—S(═O) 2 —R 16b  moiety; 
     R 8b , R 12b , R 17b , R 18b , R 19b , R 20b , R 21b , R 22b , R 23b , R 24b , R 25b , R 26b , R 27b , R 28b , R 29b , R 30b , R 31b , R 32b  and R 33b , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group; 
     R 9b  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 10b  and R 11b , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13b  and R 14b , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13b  and R 14b  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15b  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16b  moiety; 
     R 16b  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     A b  and B b  together with the bridging carbon form an unsubstituted or at least mono-substituted, saturated or unsaturated cycloaliphatic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     D b  and E b  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     D b  and E b , independently of one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Ih) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1h  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) mh —NR 13h R 14h  moiety with mh=0, 1, 2, 3, 4 or 5; 
     R 2h  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10h ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3h  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10h ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) nh —NR 13h R 14h  moiety with nh=0, 1, 2, 3, 4 or 5; 
     R 4h , R 5h  and R 7h , independently of one another, each represent a hydrogen atom; —NO 2 ; —CN; —O—R 10h ; —C(═O)—OR 12h ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 10h  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13h  and R 14h , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13h  and R 14h  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15h  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16h  moiety; 
     and R 16h  represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ih) are those, wherein 
     R 1h  represents a hydrogen atom or a —(CH 2 ) mh —NR 13h R 14h  radical, 
     R 2h , and R 7h  each represent hydrogen, 
     R 3h  represents a hydrogen atom, 1-methyl-piperidin-4-yl or a —(CH 2 ) nh —NR 13h R 14h  moiety with nh=0, 1 or 2, 
     R 4h  represents chlorine, bromine or a hydrogen atom, 
     R 4h  K represents —C(═O)—O—C 2 H 5  or a hydrogen atom, 
     R 15h  represents hydrogen or a —S(═O) 2 —R 16h  moiety, 
     R 13h  and R 14h , identical or different, each represent methyl, ethyl, isopropyl or n-propyl, more preferably methyl, 
     or 
     R 13h  and R 14h , together with the bridging nitrogen atom form a 5- or 6-membered heterocyclic ring, more preferably form a pyrrolidine ring or a piperidine ring 
     and 
     R 16h  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, thiophenyl, benzo[b]furanyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazoly1 which may be substituted by 1, 2 or 3 substituents selected from the group consisting of chlorine, methyl, phenyl and —O-phenyl and/or which may be bonded via a C 1-2  alkylene group, 
     and mh is 0, 1 or 2, 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Ih) are those selected from the group consisting of: 
     [788] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [789] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-naphthalene-2-sulfonamide, 
     [790] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-naphthalene-1-sulfonamide, 
     [791] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide, 
     [792] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-4-phenylbenzenesulfonamide, 
     [793] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-2-(naphthalene-1-yl)-ethanesulfonamide, 
     [794] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-4-phenoxybenzenesulfonamide, 
     [795] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-3,5-dichlorobenzenesulfonamide, 
     [796] 5-Chloro-3-methyl-N-[1-[2-(pyrrolidin-1-yl)ethyl-1H-indol-6-yl]-benzo[b]thiophene-2-sulfonamide, 
     [797] N-(1-[2-(Pyrrolidin-1-yl)ethyl]-1H-indol-6-yl]-napthyl-2-sulfonamide, 
     [798] N-[1-[2-Pyrrolidin-1-yl]ethyl]-1H-indol-6-yl]-naphthalene-1-sulfonamide, 
     [799] 6-Chloro-N-[1-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-6-yl]-imidazo[2,1-b]thiazole-5-sulfonamide, 
     [800] 4-Phenyl-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-6-yl)-benzenesulfonamide 
     [801] 2-(Naphth-1-yl)-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-6-yl)-ethansulfonamide, 
     [802] 4-Phenoxy-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-6-yl)-benzenesulfonamide 
     [803] 3,5-Dichloro-N-(1-(2-(pyrrolidin-1-yl)-1H-indol-6-yl)-benzenesulfonamide, 
     [804] 5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [805] N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)naphthalene-2-sulfonamide, 
     [806] N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)naphthalene-1-sulfonamide, 
     [807] 6-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-6-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [808] N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)-4-phenylbenzenesulfonamide, 
     [809] N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)-4-phenoxybenzenesulfonamide, 
     [810] 3,5-dichloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)benzenesulfonamide, 
     [811] 4,5-dichloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-6-ypthiophene-2-sulfonamide, 
     [812] 5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-6-yl)naphthalene-1-sulfonamide, 
     [813] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [814] N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)naphthalene-2-sulfonamide, 
     [815] N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)naphthalene-1-sulfonamide, 
     [816] 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [817] N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)-4-phenylbenzenesulfonamide, 
     [818] N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)-2-(naphthalen-1-yl)ethanesulfonamide, 
     [819] N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)-4-phenoxybenzenesulfonamide, 
     [820] 3,5-dichloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)benzenesulfonamide, 
     [821] 4,5-dichloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-ypthiophene-2-sulfonamide, 
     [822] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-6-yl)naphthalene-1-sulfonamide, 
     [823] 6-bis(6-chloroimidazo[2,1-b]thiazol-5-ylsulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole, 
     [824] 6-bis(3,5-dichlorobenzenesulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole, 
     [825] 6-bis(4,5-dichlorothiophene-2-sulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole, 
     [826] 6-bis(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)amino-3-(2-(dimethylamino)-1-ethoxyethyl)-1H-indole 
     [827] Ethyl 6-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonamido)-3-(1-methylpiperidin-4-yl)-1H-indole-5-carboxylate, 
     [828] N-(4-bromo-3-(1-methylpiperidin-4-yl)-1H-indol-6-yl)naphthalene-1-sulfonamide, 
     [829] N-(7-bromo-3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)benzofuran-2-sulfonamide, 
     [830] N-(7-methoxy-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)benzo[c][1,2,5]thiadiazole-4-sulfonamide, 
     [831] N-(7-methoxy-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide and 
     [832] 6-chloro-N-(7-methoxy-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-ypimidazo[2,1-b]thiazole-5-sulfonamide; 
     and their corresponding salts and solvates. 
     The compounds of general formula (Ih) can be prepared according to the disclosure of WO 2005/013976 and WO 2006/024535. The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Ik) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1k  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted phenyl radical or an unsubstituted or at least mono-substituted benzyl radical; 
     R 3k  represents a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) nk —NR 13k R 14k  moiety with nk=0, 1, 2, 3, 4 or 5; 
     R 13k  and R 14k , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13k  and R 14k  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15k  represents a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     and R 16k  represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ik) are those, wherein 
     nk represents 0, 1, 2, 3 or 4; 
     R 1k  represents hydrogen, 
     R 3k  represents a —NR 13k R 14k  moiety or a moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     wherein, if present, the dotted line represents an optional chemical bond and Y represents hydrogen, a methyl group or an ethyl group, 
     R 15k  represents hydrogen, a methyl group or an ethyl group, 
     R 13k  and R 14k , identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group, or 
     R 13k  and R 14k  together with the bridging nitrogen atom form a moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     wherein Z represents hydrogen, a methyl group or an ethyl group, 
     R 16k  represents a moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     wherein 
     R a  and R b  are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, ethyl, pyridinyl, thiophenyl and furyl, 
     R c , R d  and R e  are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, ethyl, methoxy, ethoxy and —CF 3 , 
     W represents a single chemical bond between the two rings, a CH 2 -group, O, S or a NR f -moiety, wherein R f  is hydrogen, methyl or ethyl, 
     m is 0, 1, 2, 3 or 4; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Ik) are those selected from the group consisting of: 
     [833] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [834] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [835] Hydrochloride N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [836] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-3,5-dichlorobenzenesulphonamide, 
     [837] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-4-phenylbenzenesulphonamide, 
     [838] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chlorothiophene-2-sulphonamide, 
     [839] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [840] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [841] N-[3-(2-dimethylamino-ethyl)-1H-indol-5-yl]-6-chloroimidazo[2,1-b]thiazol-5-sulphonamide, 
     [842] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [843] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide hydrochloride, 
     [844] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [845] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]naphthalene-1-sulphonamide hydrochloride, 
     [846] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]-5-chlorothiophene-2-sulphonamide, 
     [847] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]-4-phenylbenzenesulphonamide, 
     [848] N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]quinoline-8-sulphonamide, 
     [849] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]naphthalene-2-sulphonamide, 
     [850] N-[3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [851] N-[3-(4-methylpiperazin-1-yl)methyl-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [852] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-(2-pyridipthiophene-2-sulphonamide, 
     [853] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-2,1,3- benzothiadiazol-4-sulphonamide, 
     [854] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]quinoline-8-sulphonamide, 
     [855] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-2-sulphonamide, 
     [856] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-4-phenoxybenzenesulphonamide, 
     [857] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-4-phenylbenzenesulphonamide, 
     [858] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-N-ethyl-naphthalene-2-sulphonamide, 
     [859] N-{3-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [860] N-{3-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}naphthalene-1-sulphonamide, 
     [861] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]naphthalene-2-sulphonamide, 
     [862] N-[3-dimethylaminomethyl-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [863] N-[3-(2-dipropylaminoethyl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [864] N-[3-(2-dipropylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [865] N-[3-(2-dibutylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [866] N-[3-(2-dibutylaminoethyl)-1H-indol-5-yl]naphthalene-1-sulphonamide, 
     [867] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-1-sulphonamide, 
     [868] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-trans-p-styrenesulphonamide, 
     [869] N-[3-(4-methylpiperazin-1-yl)methyl-1H-indol-5-yl]-trans-β-styrenesulphonamide, 
     [870] N-[3-(octahydroindolizin-7-yl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [871] N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-6-chloroimidazo[2,1-b]thiazol-5-sulphonamide, 
     [872] N-{3-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}naphthalene-2-sulphonamide, 
     [873] N-[3-(4-methylpiperazin-1-yl)methyl-1H-indol-5-yl]-α-toluenesulphonamide, 
     [874] N-[3-(3-diethylaminopropyl)-1H-indol-5-yl]naphthalene-2-sulphonamide, 
     [875] N-[3-(3-diethylaminopropyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [876] N-{3-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-5-yl}-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide, 
     [877] N-{3-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-5-yl}naphthalene-1-sulphonamide, 
     [878] N-{3-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-5-yl}naphthalene-2-sulphonamide, 
     [879] N-[3-(2-dipropylaminoethyl)-1H-indol-5-yl]naphthalene-2-sulphonamide, 
     [880] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-1-sulphonamide, 
     [881] N-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]naphthalene-2-sulphonamide, 
     [882] N-{3-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}quinoline-8-sulphonamide, 
     [883] N-{3-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}-4-phenylbenzenesulphonamide, 
     [884] N-[3-(4-methylpiperazin-1-yl)ethyl-1H-indol-5-yl]naphthalene-2-sulphonamide and 
     [885] N-[3-(4-methylpiperazin-1-yl)ethyl-1H-indol-5-yl]-5-chloronaphthalene-1-sulphonamide; 
     and their corresponding salts and solvates. 
     The compounds of general formula (Ik) can be prepared according to the disclosure of WO 2004/098588. The respective part of the literature is hereby incorporated by reference and forms part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Im) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1m  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) mm —NR 13m R 14m  moiety with mm=0, 1, 2, 3, 4 or 5; 
     R 2m  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10m ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3m  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10m ; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) nm —NR 13m R 14m  moiety with nm=0, 1, 2, 3, 4 or 5; 
     R 4m m, R 6m  an d R 7m , independently of one another, each represent a hydrogen atom; —NO 2 ; —CN; —O—R 10m ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 10m  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono- substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13m  and R 14m , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13m  and R 14m  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15m  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16m  moiety; 
     and R 16m  represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Im) are those, wherein 
     R 1m  represents a hydrogen atom, ethyl, methyl, n-propyl, n-butyl or a —(CH 2 ) mm —NR 13m R 14m  radical, 
     R 2m  represents hydrogen or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl and isopropyl, more preferably hydrogen or methyl, 
     R 3m  represents a hydrogen atom; a radical selected from the group consisting of piperidinyl, pyrrolidinyl, (1,2,3,6)-tetrahydropyridinyl and octahydroindolizinyl, which may be subsituted by 1, 2, 3 or 4 radicals selected from the group consisting of methyl, ethyl, n-propyl and n-butyl; or a —(CH 2 ) nm —NR 13m R 14m  moiety with nm=0, 1, 2, 3, 4 or 5; 
     R 4m  and R 6m  each represent hydrogen, 
     R 7m  represents a hydrogen atom, a chlorine atom, a bromine atom or —O—CH 3 , 
     R 15m  represents hydrogen, 
     R 13m  and R 14m  identical or different, each represent methyl, ethyl, n-propyl, n-butyl or isopropyl, 
     or 
     R 13m  and R 14m  together with the bridging nitrogen form a 5- or 6-membered heterocyclic ring, more preferably form a moiety selected from the group consisting of morpholine, piperazine, pyrrolidine and piperidine which may be subsituted by 1, 2, 3 or 4 radicals selected from the group consisting of methyl, ethyl, n-propyl and n-butyl; 
     R 16m  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, quinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[1,2,5]thiadiazolyl, thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2 or 3 substituents selected from the group consisting of fluorine, bromine, chlorine, methyl, phenyl, pyridinyl, nitro, —C(═O)—CH 3 , —O—CH 3  and —O-phenyl and/or which may be bonded via a C 1-2  alkylene group or a C 2  alkenylene group, 
     and 
     mm is 2 or 3, 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Im) are those selected from the group consisting of 
     [886] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [887] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide, 
     [888] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide, 
     [889] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloronaphthalene-1-sulfonamide, 
     [890] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzenesulfonamide, 
     [891] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-quinoline-8-sulfonamide, 
     [892] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-phenoxybenzenesulfonamide, 
     [893] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methylbenzenesulfonamide, 
     [894] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chlorothiophene-2-sulfonamide, 
     [895] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzo[1,2,5]thiadiazole-4-sulfonamide, 
     [896] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide, 
     [897] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3,5-dichlorobenzenesulfonamide, 
     [898] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-bromobenzenesulfonamide, 
     [899] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-nitrobenzenesulfonamide, 
     [900] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-1-phenylmethanesulfonamide, 
     [901] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide, 
     [902] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide, 
     [903] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [904] trans-N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-2-phenylethenesulfonamide, 
     [905] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4,5-dichlorothiophene-2-sulfonamide, 
     [906] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-acetylbenzenesulfonamide, 
     [907] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-bromobenzenesulfonamide, 
     [908] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methoxybenzenesulfonamide, 
     [909] N-[3-(2-diethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [910] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-nitrobenzenesulfonamide, 
     [911] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-fluorobenzenesulfonamide, 
     [912] N-[1-(2-diethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide, 
     [913] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide, 
     [914] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-2-sulfonamide, 
     [915] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-1-sulfonamide, 
     [916] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-4-phenylbenzenesulfonamide, 
     [917] 5-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [918] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-2-sulfonamide, 
     [919] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-1-sulfonamide, 
     [920] 6-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [921] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenylbenzenesulfonamide, 
     [922] N-(1-(2-dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-2-(naphth-1-yl)-ethanesulfonamide, 
     [923] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenoxy-benzenesulfonamide, 
     [924] 3,5-dichloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-benzenesulfonamide, 
     [925] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide, 
     [926] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide 
     [927] N-(1-(2-(dimethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide, 
     [928] 5-chloro-3-methyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [929] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [930] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [931] 6-chloro-N-(1-(3-piperidin-1-yl)propyl)-1H-indol-5-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [932] 4-phenyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide, 
     [933] 2-(naphth-1-yl)-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-ypethanesulfonamide, 
     [934] 4-phenoxy-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide, 
     [935] 3,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonylamide, 
     [936] 4,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)thiophene-2-sulfonamide and 
     [937] 5-chloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [938] N-(3-(2-(diethylamino)ethyl)-7-methoxy-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [939] N-(3-(2-(diethylamino)ethyl)-7-methoxy-1H-indol-5-yl)benzo[c][1,2,5]thiadiazole-4-sulfonamide, 
     [940] 6-chloro-N-(3-(2-(diethylamino)ethyl)-7-methoxy-1H-indol-5-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [1132] 5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1133] N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1134] N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide hydrochloride, 
     [1135] 3,5-dichloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)benzenesulfonamide, 
     [1136] N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)biphenyl-4-sulfonamide, 
     [1137] 5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)thiophene-2-sulfonamide, 
     [1138] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1139] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1140] 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [1141] 5-chloro-3-methyl-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [1142] 5-chloro-3-methyl-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide hydrochloride, 
     [1143] N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1144] N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)naphthalene-1-sulfonamide hydrochloride, 
     [1145] 5-chloro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)thiophene-2-sulfonamide, 
     [1146] N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)biphenyl-4-sulfonamide, 
     [1147] N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)quinoline-8-sulfonamide, 
     [1148] N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1149] N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1150] 5-chloro-3-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [1151] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide, 
     [1152] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)benzo[c][1,2,5]thiadiazole-4-sulfonamide, 
     [1153] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)quinoline-8-sulfonamide, 
     [1154] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1155] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-4-phenoxybenzenesulfonamide, 
     [1156] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)biphenyl-4-sulfonamide, 
     [1157] N-(3-(2-(diethylamino)ethyl)-1-ethyl-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1158] 5-chloro-3-methyl-N-(3-(2-morpholinoethyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [1159] N-(3-(2-morpholinoethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1160] N-(3-(2-(diethylamino)ethyl)-1-methyl-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1161] 5-chloro-N-(3-((dimethylamino)methyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1162] N-(3-(2-(dipropylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1163] 5-chloro-N-(3-(2-(dipropylamino)ethyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1164] 5-chloro-N-(3-(2-(dibutylamino)ethyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1165] N-(3-(2-(dibutylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1166] 5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1167] N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)-2-phenylethenesulfonamide, 
     [1168] N-(3-((4-methylpiperazin-1-yl)methyl)-1H-indol-5-yl)-2-phenylethenesulfonamide, 
     [1169] 5-chloro-3-methyl-N-(3-(octahydroindolizin-7-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [1170] 6-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-5-yl)-5,7a-dihydroimidazo[2,1-b]thiazole-5-sulfonamide, 
     [1171] N-(3-(2-morpholinoethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1172] N-(3-((4-methylpiperazin-1-yl)methyl)-1H-indol-5-yl)(phenyl)methanesulfonamide, 
     [1173] N-(3-(3-(diethylamino)propyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1174] 5-chloro-N-(3-(3-(diethylamino)propyl)-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [1175] 5-chloro-3-methyl-N-(3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 
     [1176] N-(3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1177] N-(3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1178] N-(3-(2-(dipropylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1179] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide, 
     [1180] N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide, 
     [1181] N-(3-(2-morpholinoethyl)-1H-indol-5-yl)quinoline-8-sulfonamide, 
     [1182] N-(3-(2-morpholinoethyl)-1H-indol-5-yl)biphenyl-4-sulfonamide, 
     [1183] N-(3-(2-(4-methylpiperidin-1-yl)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide and 
     [1184] 5-chloro-N-(3-(2-(4-methylpiperidin-1-yl)ethyl)-1H-indol-5-yl)naphthalene-1-sulfonamide; 
     and their corresponding salts and solvates. 
     The compounds of general formula (Im) can be prepared according to the disclosure of WO 2003/042175, WO 2005/013977 and WO 2006/024535. The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (In) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1n  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) mn —NR 13n R 14n  moiety with mn=0, 1, 2, 3, 4 or 5; 
     R 2n  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10n n; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3n  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10n ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) nn —NR 13n R 14n  moiety with nn=0, 1, 2, 3, 4 or 5; 
     R 5n , R 6n  and R 7n , independently of one another, each represent a hydrogen atom; —NO 2 ; —CN; —O—R 10n ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 10n  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13n  and R 14n , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13n  n and R 14n  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15n  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16n  moiety; 
     R 16n  represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (In) are those, wherein 
     R 1n  represents a hydrogen atom or a —(CH 2 ) mn —NR 13n R 14n  radical, 
     R 2n , R 5n , R 6n  and R 7n  each represent hydrogen, 
     R 3n  represents a hydrogen atom or a —(CH 2 ) nn —NR 13n R 14n  moiety with nn=0, 1 or 2; 
     R 15n  represents hydrogen, 
     R 13n  and R 14n , identical or different, each represent methyl, ethyl, n-propyl, isopropyl, more preferably methyl, 
     or 
     R 13n  and R 14n  together with the bridging nitrogen form a 5- or 6-membered heterocyclic ring, more preferably form pyrrolidine or piperidine, 
     and 
     R 16n  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2 or 3 substituents selected from the group consisting of chlorine, methyl, phenyl and —O-phenyl and/or which may be bonded via a C 1-2  alkylene group, and 
     mn is 1 or 2; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (In) are those selected from the group consisting of: 
     [941] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [942] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-2-sulfonamide, 
     [943] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-1-sulfonamide, 
     [944] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide, 
     [945] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphtalene-1-yl)-ethanesulfonamide, 
     [946] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide, 
     [947] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5- dichlorobenzenesulfonamide and 
     [948] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide 
     [949] N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)-4-biphenylsulfonamide, 
     [950] N-(3-(2-(d imethylamino)ethyl)-1H-indol-4-yl)-4-phenoxybenzenesulfonamide, 
     [951] 3,5-dichloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)benzenesulfonamide, 
     [952] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)-3-methylbenzo[b]thiophene-2-sulfonamide, 
     [953] N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)naphthalene-1-sulfonamide, 
     [954] 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)naphthalene-2-sulfonamide, 
     [955] N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)naphthalene-2-sulfonamide, 
     [956] 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-ypimidazo[2,1-b]thiazole-5-sulfonamide, 
     [957] N-(3-(2-(dimethylamino)ethyl)-1H-indol-4-yl)-2-(naphthalen-1-yl)ethanesulfonamide, 
     and their corresponding salts and solvates. 
     The compounds of general formula (In) can be prepared according to the disclosure of WO 2005/13978 and WO 2006/024535. The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Io) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1o  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) mo —NR 13o R 14o  moiety with mo=0, 1, 2, 3, 4 or 5; 
     R 2o  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10o ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3o  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —CN; —O—R 10o ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; a —CH(OC 2 H 5 )—CH 2 —NR 13o R 14o  moiety or a —(CH 2 ) no —NR 13o R 14o  moiety with no=0, 1, 2, 3, 4 or 5; 
     R 4o , R 5o  and R 6o , independently of one another, each represent a hydrogen atom; —NO 2 ; —CN; —O—R 10o ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 10o  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13o  and R 14o , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13o  and R 14o  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15o  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16o  moiety; 
     and R 16o  represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Io) are those, wherein 
     R 1  is —(CH 2 ) mo —NR 13o R 14o  radical, 
     R 2o , R 4o  and R 6o  each represent hydrogen, 
     R 3o  represents a hydrogen atom, a —CH(OC 2 H 5 )—CH 2 —NR 13o R 14o  moiety or a —(CH 2 ) no —NR 13o R 14o  moiety with no=0, 1 or 2, 
     R 5o  represents a hydrogen atom, chlorine or bromine, 
     R 15o  represents hydrogen or a —S(═O) 2 —R1 6o  moiety, 
     R 13o  and R 14o , identical or different, each represent methyl, ethyl, n-propyl or isopropyl, more preferably methyl, 
     or 
     R 13o  and R 14o  together with the bridging nitrogen atom form a 5- or 6-membered heterocyclic ring, more preferably form a pyrrolidine or piperidine ring, 
     R 16o  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl which may be substituted by 1, 2 or 3 substituents selected from the group consisting of chlorine, methyl and phenyl and/or which may be bonded via a C 1 - 2  alkylene group, 
     and 
     no is 1 or 2; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Io) are those selected from the group consisting of:
         N-[1-(2-dimethylaminoethyl)-1H-indole-7-yl]-naphtalene-1-sulfonamide,   N-[1-(2-dimethylaminoethyl)-1H-indole-7-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,   N-[1-(2-dimethylaminoethyl)-1H-indole-7-yl]-4-phenylbenzenesulfonamide and   N-[1-(2-dimethylaminoethyl)-1H-indole-7-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide   5-chloro-3-methyl-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-7-yl)-benzo[b]thiophen-2-sulfonamide,   N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-7-yl)naphthalene-1-sulfonamide,   6-chloro-N-(1-(2-(pyrroldin-1-yl)ethyl)-1H-indol-7-yl)imidazo[2,1-b]thiazole-5-sulfonamide and   2-(naphth-1-yl)-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-7-yl)ethansulfonamide   5-chloro-N-(3-(2-(dimethylamino)-1-ethoxyethyl)-1H-indol-7-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,   5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-7-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,   7-bis(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)amino-3-(2-(diethylamino)-1-ethoxyethyl)-1H-indole,   5-chloro-N-(3-(2-(diethylamino)-1-ethoxyethyl)-1H-indol-7-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,   7-bis(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole,   7-bis(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)amino-3-(2-(diethylamino)ethyl)-1H-indole,   5-chloro-N-(3-(2-(diethylamino)ethyl)-1H-indol-7-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,   7-bis(6-chloroimidazo[2,1-b]thiazol-5-ylsulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole,   N-(5-bromo-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-7-yl)-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,       

     and their corresponding salts and solvates. 
     The compounds of general formula (Io) can be prepared according to the disclosure of WO 2005/13979 and WO 2006/024535. The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Ip) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1p  represents a —S(═O) 2 —R 9p  moiety or a —S(═O) 2 —C(H)A p B p  moiety; 
     R 2p  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —OH; —CN; —O—R 10p ; —S—R 11p ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3p  represents a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via an unsubstituted or at least mono-substituted alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or a —(CH 2 ) np —NR 13p R 14p  moiety with np=0, 1, 2, 3, 4 or 5; 
     R 4p , R 5p , R 6p  and R 7p , independently of one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —OH; —CN; —C(═O)—R 8p ; —O—R 10p ; —S—R 11p ; —NH—R 17p ; —NR 18p R 19p ; atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group; 
     R 8p  represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 8p , R 17p , R 18p  and R 19p , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group; 
     R 9p  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 10p  and R 11p , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 13p  and R 14p , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 13p  and R 14p  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     A p  and B p  together with the bridging carbon form an unsubstituted or at least mono-substituted, saturated or unsaturated cycloaliphatic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ip) are those, wherein 
     R 1p  represents a —S(═O) 2 —C(H)A p B p  moiety; 
     R 1p , R 3p , R 4p  and R 6p  each represent hydrogen, 
     R 3p  represents a —(CH 2 ) np —NR 13p R 14p  moiety or an unsaturated, optionally at least one nitrogen atom as a ring member containing 5- or 6-membered cycloaliphatic radical, which may be substituted by a methyl group and/or which may be condensed with a 5-membered cycloaliphatic ring, more preferably R 3p  represents a —(CH 2 ) np —NR 13p R 14p  moiety or a moiety selected from the group consisting of 
     R 5p  represents H, fluorine, chlorine, nitro or a —NH 2  group, 
     
       
         
         
             
             
         
       
     
     R 13p  and R 14p , identical or different, each represent methyl, ethyl, n-propyl or isopropyl, more preferably methyl, 
     or 
     R 13p  and R 14p  together with the bridging nitrogen atom form a 5- or 6-membered heterocyclic ring, more preferably form a pyrrolidine or piperidine ring, 
     A p  and B p  together with the carbon atom to which they are bonded form a saturated or unsaturated C 3 -C 8  cycloaliphatic ring, more preferably form a cyclohexyl ring, 
     and 
     np is 0, 1 or 2; 
     optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Ip) are those selected from the group consisting of
         1-Cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole,   5-chloro-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,   5-Amino-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole and   1-Cyclohexanesulfonyl-5-fluoro-3-(1,2,3,5,8,8a-hexahydro-indolizine-7-yl)-1H-indole hydrochloride       

     and their corresponding salts and solvates. 
     The compounds of general formula (Ip) can be prepared according to the disclosure of WO 2005/013974. The respective part of the literature is hereby incorporated by reference and forms part of the present disclosure. 
     Preferred compounds of general formula (Ib) are selected from the group consisting of compounds of general formula (Iq) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1q  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, 
     which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; a —C(═O)—R 8q  moiety; a —S(═O) 2 —R 9q  moiety; 
     R 2q  represents a hydrogen atom; —F; —Cl; —Br; —I; —NO 2 ; —NH 2 ; —SH; —OH; —CN; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a chain member containing aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 4q , R 5q , R 6q  and R 7q , independently of one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O) 2 —OH; —C(═O)—NH 2 ; —S(═O) 2 —NH 2 ; —C(═O)—R 8q ; —S(═O) 2 —R 9q ; —O—R 10q ; —S—R 11q ; —C(═O)—OR 12q ; —N(R 15q )—S(═O) 2 —R 16q ; —NH—R 17q ; —NR 18q R 19q ; —C(═O)—NHR 20q , —C(═O)—NR 21q R 22q ; —S(═O) 2 —NHR 23q ; —S(═O) 2 —NR 24q R 25q ; —O—C(═O)—R 26q ; —NH—C(═O)—R 27q ; —NR 28q —C(═O)—R 29q ; NH—C(═O)—O—R 30q ; NR 31q —C(═O)—O—R 32q ; —S(═O) 2 —O—R 33q ; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     with the proviso that at least one of the substituents R 4q , R 5q , R 6q  and R 7q  represents a —N(R 15q )—S(═O) 2 —R 16q  moiety; 
     R 8q , R 12q , R 17q , R 18q , R 19q , R 20q , R 21q , R 22q , R 23q , R 24q , R 25q , R 26q , R 27q , R 28q , R 29q , R 30q , R 31q , R 32q  and R 33q , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group; 
     R 9q represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 10q  and R 11q , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group; 
     R 15q  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O) 2 —R 16q  moiety; 
     R 16q  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     D q  and E q  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     or 
     D q  and E q , independently of one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Iq) are those, wherein 
     pq is 0, 
     R 1q  represents a hydrogen atom, 
     R 2q  represents a hydrogen atom, 
     D q  and E q , identical or different, represent an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, 
     one of the substituents R 4q , R 5q , R 6q and R 7q  represents an —N(R 15q )—S(═S)—R 16q -moiety while the other three of these substituents each represent a hydrogen atom, 
     R 15q  represents a hydrogen atom, 
     R 16q  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, pyrazolyl, thiophenyl (thiophenyl), benzo[b]-thiophenyl, benzo[b]furanyl, quinolinyl, isoquinolinyl, imidazo[2,1-b]thiazolyl, 2-oxo-2,3-dihydro-benzooxazolyl and 2-oxo-2,3-dihydrobenzo[d]thiazolyl, whereby said aryl or heteroaryl radical may be bonded via a —(CH 2 ) 1, 2 or 3 — group and/or may be substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br, I, —CN, —CF 3 , —CF 2 H, CFH 2 , —C(═O)—O—CH 3 , C(═O)—O—CH 2 —CH 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Particularly preferred compounds of general formula (Iq) are those selected from the group consisting of:
         2-[5-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonylamino)-1H-indol-3-yl]-N,N-diethyl-2-oxoacetamide,   N,N-Diethyl-2-[5-(naphthalene-2-sulfonylamino)-1H-indol-3-yl]-2-oxo-acetamide,   N,N-Diethyl-2-[5-(naphthalene-1-sulfonylamino)-1H-indol-3-yl]-2-oxo-acetamide,   2-[5-(Biphenyl-4-sulfonylamino)-1H-indol-3-yl]-N,N-diethyl-2-oxo-acetamide,   N,N-Diethyl-2-oxo-2-[5-(quinoline-8-sulfonylamino)-1H-indol-3-yl]-acetamide,   N,N-Dimethyl-2-[5-(naphthalene-2-sulfonylamino)-1H-indol-3-yl]-2-oxo-acetamide,   N,N-Dimethyl-2-[5-(naphthalene-1-sulfonylamino)-1H-indol-3-yl]-2-oxo-acetamide,   2-[5-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonylamino)-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide,   2-[5-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonylamino)-1H-indol-3-yl]-N,N-diethyl-2-oxo-acetamide,   2-[5-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonylamino)-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide,   N,N-Dimethyl-2-[4-(naphthalene-1-sulfonylamino)-1H-indol-3-yl]-2-oxo-acetamide,   2-[4-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonylamino)-1H-indole-3-yl]-N,N-dimethyl-2-oxo-acetamide,   2-[4-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonylamino)-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide,   N,N-Dimethyl-2-[5-[(4-fluoro-3-methyl-phenyl)-1-sulfonylamino]-1H-indol-3-yl]-2-oxo-acetamide,   5-(3-Dimethylaminooxalyl-1H-indol-5-ylsulfamoyl)-3-methyl-benzofuran-2-carboxylic acid ethyl ester,   2-[5-(Biphenyl-4-sulfonylamino)-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide,   N,N-Dimethyl-2-oxo-2-[5-(2-oxo-2,3-dihydro-benzoxazole-6-sulfonylamino)-1H-indol-3-yl]acetamide,   N,N-Dimethyl-2-oxo-2-[5-(2-oxo-2,3-dihydrobenzo[d]thiazole-6-sulfonamido)-1H-indol-3-yl]acetamide,   2-[5-[(4-Cyclohexyl-phenyl)-1-sulfonylamino]-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide,   N,N-Dimethyl-2-[5-[(4-phenoxy-phenyl)-1-sulfonylamino]-1H-indol-3-yl]-2-oxo-acetamide,   2-(5-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonamido)-2-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   2-(5-(6-chloroimidazo[2,1-b]thiazole-5-sulfonamido)-2-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   2-(6-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   N,N-dimethyl-2-(6-(naphthalene-3-sulfonamido)-1H-indol-3-yl)-2-oxoacetamide   2-(6-(biphenyl-4-sulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   N,N-dimethyl-2-(6-(naphthalene-1-sulfonamido)-1H-indol-3-yl)-2-oxoacetamide,   N,N-dimethyl-2-(6-(2-(naphthalen-1-yl)ethylsulfonamido)-1H-indol-3-yl)-2-oxoacetamide,   N,N-dimethyl-2-oxo-2-(6-(4-phenoxyphenylsulfonamido)-1H-indol-3-yl)acetamide,   2-(6-(3,4-dichlorothiophene-2-sulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   2-(6-(3,5-dichlorophenylsulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   2-(6-(1-chloronaphthalene-6-sulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   2-(6-(6-chloroimidazo[2,1-b]thiazole-5-sulfonamido)-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide,   N,N-diethyl-2-(2-methyl-5-(5-methyl-1-phenyl-1H-pyrazole-4-sulfonamido)-1H-indol-3-yl)-2-oxoacetamide and   N,N-diethyl-2-(2-methyl-5-(1,3,5-trimethyl-1H-pyrazole-4-sulfonamido)-1H-indol-3-yl)-2-oxoacetamide;       

     and their corresponding salts and solvates. 
     The compounds of general formula (Iq) can be prepared according to the disclosure of WO 2006/015867. The respective part of the literature is hereby incorporated by reference and forms part of the present disclosure. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of indazolyl- and (2,3)-dihydro-indolyl-derived sulfonamide compounds of general formula (Ic) 
     
       
         
         
             
             
         
       
     
     wherein 
     X c —Y c  from left to right represents CR 1c ═N and Z c  is N[(CH 2 ) nc R 6c ] 
     or 
     X c —Y c  from left to right represents CR 7c ═N, Z c  is NH, R 7c  represents the following moiety 
     
       
         
         
             
             
         
       
     
     A c  represents CH or N and B c  represents NR 8c , O or S; 
     X c —Y c  from left to right represents C[(CH 2 ) nc R 9c ]═N and Z c  is NR 10c    
     or 
     X c —Y c  represents CH 2 —CH 2  and Z c  is N[(CH 2 ) nc R 11c ]; 
     nc is 0, 1, 2, 3 or 4; 
     R 1c  represents a hydrogen atom; NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—R 12c ; —OR 13c ; —SR 14c ; —F; —Cl, —Br; —I; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 2c , R 3c , R 4c  and R 5c , independently of one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 12c ; —OR 13c ; —SR 14c ; —N(R 15c )—S(═O) 2 —R 16c ; —NH—R 17c ; —NR 18c R 19c ; —F; —Cl, —Br; —I; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c  represents a —N(R 15c )—S(═O) 2 —R 16c  moiety; 
     R 6c , R 9c  and R 11c , independently of one another, each represent a —NR 20c R 21c  radical 
     or 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 8c  represents —C(═O)—R 22c ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 10c  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a —S(═O) 2 —R 23c  moiety; 
     R 12c , R 13c , R 14 c , R 17c , R 18c  and R 19c , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 15c  represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a —S(═O) 2 —R 24c  moiety; 
     R 16c  and R 24c , independently of one another, each represent an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 20c  and R 21c , independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or R 20c  and R 21c  together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 22c  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     and 
     R 23c  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ic) are selected from the group consisting of compounds of general formula (Ir) 
     
       
         
         
             
             
         
       
     
     wherein 
     nr is 0, 1 or 2; 
     R 1r  represents a hydrogen atom or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     R 2r , R 3r , R 4r  and R 5 r, independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —N(R 15r )—S(═O) 2 —R 16r ; F; Cl; Br; I; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     with the proviso that at least one of the substituents R 2r , R 3r , R 4r  and R 5r  represents a —N(R 15r )—S(═O) 2 —R 16r  moiety; 
     R 6r  represents a —NR 20r R 21r  radical; 
     R 15r  represents a hydrogen atom or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl 
     R 16r  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]furanyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br, I, —CN, phenyl, phenoxy and benzyl 
     and 
     R 20r  and R 21r , independent from one another, each represent an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Particularly preferred compounds of general formula (Ir) are those selected from the group consisting of:
         N-(1-(2-(Dimethylamino)ethyl)-1H-indazol-6-yl)napthalene-2-sulfonamide and   5-chloro-N-(1-(2-(dimethylamino)ethyl)-1H-indazol-6-yl)-3-methylbenzo[b]thiophene-2-sulfonamide;       

     optionally in form of a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Preferred compounds of general formula (Ic) are selected from the group consisting of compounds of general formula (Is) 
     
       
         
         
             
             
         
       
     
     wherein 
     A s  represents CH and B s  represents NR 8s    
     or 
     A s  represents N and B s  represents NR 8s    
     or 
     A s  represents N and B s  represents O 
     or 
     A s  represents N and B s  represents S; 
     R 2s , R 3s , R 4s  and R 5s , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —N(R 15s )—S(═O) 2 —R 16s ; F; Cl; Br; I; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     with the proviso that at least one of the substituents R 2s , R 3s , R 4s  and R 5s  represents a —N(R 15s )—S(═O) 2 —R 16s  moiety; 
     R 8s  represents an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     R 15s  represents a hydrogen atom or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl 
     and 
     R 16s  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]furanyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br, I, —CN, phenyl, phenoxy and benzyl; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Particularly preferred compounds of general formula (Is) are those selected from the group consisting of:
         Naphthalene-2-sulfonic acid[3-(1-methyl-piperidin-4-yl)-1H-indazol-5-yl]-amide,   5-chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid[3-(1-methyl-piperidin-4-yl)-1H-indazol-5-yl]-amide,   Naphthalene-1-sulfonic acid[3-(1-methyl-piperidin-4-yl)-1H-indazol-5-yl]-amide,   4-Phenylbenzene-4-sulfonic acid[3-(1-methyl-piperidin-4-yl)-1H-indazol-5-yl]-amide,   N-[3-(1-Methyl-piperidin-4-yl)-1H-indazol-5-yl]-4-phenoxy-benzenesulfonamide and   N-[3-(1-Methyl-piperidin-4-yl)-1H-indazol-5-yl]benzenesulfonamide;       

     optionally in form of a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Preferred compounds of general formula (Ic) are selected from the group consisting of compounds of general formula (It) 
     
       
         
         
             
             
         
       
     
     wherein 
     nt is 0, 1 or 2; 
     R 2t , R 3t , R 4t  and R 5t , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —N(R 15t )—S(═O) 2 —R 16t ; F; Cl; Br; I; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     with the proviso that at least one of the substituents R 2t , R 3t , R 4t  and R 5t  represents a —N(R 15t )—S(═O) 2 —R 16t  moiety; 
     R 9t  represents a —NR 20t R 21t  radical; 
     R 10t  represents an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl or a —S(═O) 2 —R 23t  moiety; 
     R 15t  represents a hydrogen atom or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl 
     R 16t  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]furanyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br, I, —CN, phenyl, phenoxy and benzyl. 
     R 20t  and R 21t , independent from one another, each represent an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, 
     isobutyl and tert-butyl; 
     or 
     R 20t  and R 21t  together with the bridging nitrogen atom form an unsubstituted moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     wherein, if present, the dotted line represents an optional chemical bond; 
     and 
     R 23t  represents an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl 
     or an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, benzo[b]furanyl, benzo[b]thiophenyl and imidazo[2,1-b]thiazolyl, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, F, Cl, Br, I, —CN, phenyl, phenoxy and benzyl; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ic) are selected from the group consisting of compounds of general formula (Iu) 
     
       
         
         
             
             
         
       
     
     wherein 
     nu is 0, 1 or 2; 
     R 2u , R 3u , R 4u  and R 5u , independent from one another, each represent a hydrogen atom; —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R 12u ; —OR 13u ; —SR 14u ; —N(R 15u )—S(═O) 2 —R 16u ; —NH—R 17u ; —NR 18u R 19u ; F; Cl; Br; I; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN and —S—CH 3 ; 
     with the proviso that at least one of the substituents R 2u , R 3u , R 4u  and R 5u  represents a —N(R 15u )—S(═O) 2 —R 16u  moiety; 
     R 11u  represents a —NR 20u R 21u  radical 
     or 
     a (hetero)cycloaliphatic radical selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     whereby each of these afore mentioned cyclic moieties may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, —O—CH 3 , —O—C 2 H 5 , —S—CH 3 , —S—C 2 H 5 , —C(═O)—OH, —C(═O)—O—CH 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NO 2 , —CHO, —CF 2 H and —CFH 2  in any position including the —NH groups and is not bonded via a nitrogen atom and, if present, the dotted line represents an optional chemical bond; 
     R 12u , R 13u , R 14u , R 17u , R 18u  and R 19u , independent from one another, each represent an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; a (hetero)cycloaliphatic radical selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl, which may be bonded via a —(CH 2 ) 1, 2 or 3 — group and which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, —O—CH 3 , —O—C 2 H 5 , —S—CH 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ; or an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl(furanyl), thiophenyl(thiophenyl) and pyrrolyl, which may be bonded via a —(CH 2 ) 1, 2 or 3 — group and which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —S—CH 2 H 5 , —C(═O)—OH, —O(═O)—O—CH 3 , —C(═O)—O—CH 2 —CH 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2 ; 
     R 15u  represents a hydrogen atom; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, —OH, —NH 2 , —SH, —O—CH 3 , —O—C 2 H 5 , —NO 2 , —CN and —S—CH 3 ; 
     R 16u  represents an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl(furanyl), thiophenyl(thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiadiazolyl, benzoxadiazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo[2,1-b]thiazolyl, which may be bonded via a —(CH 2 ) 1, 2 or 3 — group and which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of —CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, —O—CH 3 , —O—C 2 H 5 , —S—CH 3 , —S—C 2 H 5 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NO 2 , phenyl, phenoxy and benzyl; 
     and 
     R 20u  and R 21u , independent from one another, each represent a hydrogen atom; or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     or 
     R 20u  and R 21u  together with the bridging nitrogen atom form a moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     whereby each of these afore mentioned cyclic moieties may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, —O—CH 3 , —O—C 2 H 5 , —S—CH 3 , —S—C 2 H 5 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—CH 2 —CH 3 , F, Cl, Br, I, —CN, —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —N(CH 3 ) 2  and —N(C 2 H 5 ) 2  in any position including the —NH groups; and, if present, the dotted line represents an optional chemical bond; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Iu) are those selected from the group consisting of:
         N-[1-(2-Dimethylamino)ethyl)-2,3-dihydro-1H-indol-6-yl]-6-chloro-imidazo[2,1-b]thiazol-5-sulfonamide;       

     optionally in form of a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     The compounds of general formulae Ic, Ir, Is, It or Iu given above are prepared by a process, wherein at least one compound of general formula II, 
     
       
         
         
             
             
         
       
     
     wherein R 16c  has the meaning given above and X represents a leaving group, preferably a halogen atom, more preferably a chlorine atom, is reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c , represents a —NH 2  group, in a suitable reaction medium, preferably in the presence of at least one base, to yield a compound of general formula I, wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c  represents a —N(H)—S(═O) 2 —R 16c  group and R 16c  has the meaning given above, which is optionally purified and/or isolated, 
     and optionally said compound of general formula I, wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c  represents a —N(H)—S(═O) 2 —R 16c  group and R 16c  has the meaning given above, is reacted with at least one compound of general formula R 15c —X, wherein R 15c  has the meaning given above and X represents a halogen atom, preferably a chlorine atom, in a suitable reaction medium, in the presence of at least one base, preferably at least one base selected from the group consisting of metal hydroxides, metal carbonates, metal alkoxides, preferably sodium methoxide or potassium tert-butoxid, metal hydrides and organometallic compounds, preferably n-butyllithium and tert-butyllithium, 
     or with at least one compound of general formula X—S(═O) 2 —R 24c , wherein R 24c  has the meaning given above and X represents a leaving group, preferably a halogen atom, more preferably a chlorine atom, in a suitable reaction medium, preferably in the presence of at least one base, 
     to yield a compound of general formula I, wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and Rc 5  represents a —N(R 15c )—S(═O) 2 —R 16c  group and R 15c  and R 16c  have the meaning given above, which is optionally purified and/or isolated. 
     Suitable reaction media for the reaction between compounds of general formulae II and III include organic solvents, such as dialkyl ether, preferably diethyl ether, or a cyclic ether, preferably tetrahydrofuran or dioxane; or a halogenated hydrocarbon, preferably dichloromethane or chloroform; an alcohol, preferably methanol or ethanol; a dipolar aprotic solvent, preferably acetonitrile, pyridine or dimethylformamide, or any other suitable reaction medium. Of course, mixtures of at least two classes of solvents or of at least two solvents of one class may also be used. 
     The reaction between compounds of general formulae II and III is preferably carried out in the presence of at least one suitable base, for example, an inorganic base such as a hydroxide or a carbonate of an alkali metal and/or an organic base, preferably triethylamine or pyridine. 
     The reaction between compounds of general formulae II and III is preferably carried out at a temperature between −10° C. and ambient temperature, i.e. approximately 25° C. and the reaction time is preferably between 5 minutes and 24 hours. 
     Suitable reaction media for the reaction between compounds of general formula I, wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c  represents a —N(H)—S(═O) 2 —R 16c  group and R 16c  has the meaning given above and compounds of general formula R 15c —X are dialkyl ether, preferably diethyl ether, or a cyclic ether, preferably tetrahydrofuran or dioxane, a hydrocarbon, preferably toluene, an alcohol, preferably methanol or ethanol, a dipolar aprotic solvent, preferably acetonitrile, pyridine or dimethylformamide, or any other suitable reaction medium. Of course, mixtures of at least two classes of solvents or of at least two solvents of one class may also be used. 
     The afore mentioned reaction is preferably carried out at a temperature between −10° C. and ambient temperature, i.e. approximately 25° C. and the reaction time is preferably 1 and 24 hours. 
     Suitable reaction media for the reaction between compounds of general formula I, wherein X c , Y c , Z c  and R 2c  to R 5c  have the meaning given above with the proviso that at least one of the substituents R 2c , R 3c , R 4c  and R 5c  represents a —N(H)—S(═O) 2 —R 16c  group and R 16c  has the meaning given above, and compounds of general formula X—S(═O) 2 —R 24c  include organic solvents, such as dialkyl ether, preferably diethyl ether, or a cyclic ether, preferably tetrahydrofuran or dioxane; or a halogenated hydrocarbon, preferably dichloromethane or chloroform; an alcohol, preferably methanol or ethanol; a dipolar aprotic solvent, preferably acetonitrile, pyridine or dimethylformamide, or any other suitable reaction medium. Of course, mixtures of at least two classes of solvents or of at least two solvents of one class may also be used. 
     The afore mentioned reaction is preferably carried out in the presence of at least one suitable base, for example, an inorganic base such as a hydroxide or a carbonate of an alkali metal and/or an organic base, preferably triethylamine or pyridine. 
     The afore mentioned reaction is preferably carried out at a temperature between −10° C. and ambient temperature, i.e. approximately 25° C. and the reaction time is preferably between 5 minutes and 24 hours. 
     Those skilled in the art understand that the process described above can also be applied to the synthesis of compounds of general formula Ir, Is, It and Iu given above. 
     The compounds of general formula Ic, Ir, Is, It or Iu given above may be purified and/or isolated according to methods well known to those skilled in the art. Preferably, the compounds of general formula Ic, Ir, Is, It or Iu may be isolated by evaporating the reaction medium, addition of water and adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purification by chromatography or recrystallisation from a suitable solvent. 
     The compounds of general formula II are commercially available or may be prepared according to methods well known in the art, for example, analogous to the methods described in the bibliography of E. E. Gilbert, Synthesis, 1969, 1, 3. The respective part of the literature description cited above is hereby incorporated by reference and forms part of the disclosure. 
     The compounds of general formula III are commercially available or may also be prepared according to standard methods known in the prior art, for example by methods similar to those described in the literature: Savitskaya, N. V. et al. Synthesis of 5-amino-3-(b-aminoethyl)indazole. Zhurnal Obshchei Khimii (1961), 31 1924-1926; Zhang, Han-Cheng et al. Discovery and Optimization of a Novel Series of Thrombin Receptor (PAR-1) Antagonists: Potent, Selective Peptide Mimetics Based on Indole and Indazole Templates. Journal of Medicinal Chemistry (2001), 44(7), 1021-1024; Ono, Shinichiro et al. Preparation of piperidine derivatives as muscarinic receptors stimulator for treatment of schizophrenia. WO 2004069828 A1; Wrzeciono, U. et al. Synthesis and antiinflammatory activity of some indazole derivatives. Part 36. Azoles. Pharmazie (1993), 48(8); 582-584; Filla, S. A. et al. Preparation o 3-(1-methylpiperidin-4-yl)-1H-indoles and 3-(1-methylpiperidin-4-yl)4-aza-1H-indoles as 5-HT1F agonist. WO 2000/487; Dumas, J. et al. Preparation of bicyclic (hetero)aryl- and pyridine-containing diaryl ureas as Raf kinase and angiogenesis inhibitors useful in the treatment of cancer and other disorders. WO 200478748; Mueller, S. G. et al. Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders. WO 200439780; Maeno, K. Preparation of aminoalkylindazole derivatives as 5-HT2c receptor agonists. WO 98/30548; Zhao, E.-C. et al. Synthesis of dialkylaminoalkyl derivatives of indazole. Zhurnal Obshchei Khimii (1959), 29, 1012-1020. Ham, P. et al. Preparation of N-heteroaryl-4′-oxadiazolylbiphenylcarboxamides as 5HT1D antagonists. WO 9532967A1; Stenkamp, D. et al. Preparation of arylamides as melanin concentrating hormone (MCH) receptor antagonists. WO 200403974. The respective parts of the literature are hereby incorporated by reference and form part of the disclosure. 
     The compounds of general formula Ic, Ir, Is, It or Iu given above may be purified and/or isolated according to methods well known to those skilled in the art. Preferably, the compounds of general formula Ic, Ir, Is, It or Iu may be isolated by evaporating the reaction medium, addition of water and then adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purified by chromatography or recrystallisation from a suitable solvent. 
     During some synthetic reactions described above or while preparing the compounds of general formulae Ic, Ir, Is, It, Iu, II and II the protection of sensitive or reactive groups may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T. W. Greene &amp; P. G. M. Wuts and Protective Groups in Organic Chemistry, John Wiley &amp; sons, 1991. The respective parts of the description is hereby incorporated by reference and forms part of the disclosure. The protective groups may be eliminated when convenient by means well-known to those skilled in the art. 
     If the substituted indazolyl sulfonamide or 2,3-dihydro-indolyl sulfonamide compounds of general formula Ic are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents. 
     The substituted indazolyl sulfonamide or 2,3-dihydro-indolyl sulfonamide compounds of general formula Ic and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. Suitable inorganic acids include but are not limited to hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids include but are not limited to citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of phenyl-piperazine-derived compounds of general formula (Id) 
     
       
         
         
             
             
         
       
     
     wherein 
     X d  represents a —NR 1d R 2d  moiety or a —OR 3d  moiety; 
     R 1d  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     an unsubstituted or at least mono-substituted radical selected from the group consisting of adamantyl, bicyclo[2.2.1]heptyl and bicyclo[3.1.1]heptyl, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group which may contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as chain member(s); 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group which may contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as chain member(s); 
     or a —C(═O)—R 12d  moiety; 
     R 2d  represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or 
     R 1d  and R 2d  together with the bridging nitrogen form an optionally at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring which may contain at least one further heteroatom as a ring member and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3d  represents or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     R 4d , R 5d  and R 6d , independently of one another, each represent a hydrogen atom or a halogen atom; 
     or 
     R 4d  and R 6d  together with the bridging carbon atoms form an unsubstituted 5- or 6-membered heterocyclic ring which contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which together with the phenyl ring which it is fused with forms a 9- or 10-membered bicyclic aromatic ring system; 
     R 7d  and R 8d , independently of one another, each represent a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 9d  and R 10d , independently of one another, each represent a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 11d  represents a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical, which may contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as chain member(s); 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     -a-C(═O)—R 13d  moiety or a —S(═O) 2 —R 14d  moiety; 
     R 12d  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     and 
     R 13d  and R 14d , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group which may contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as chain member(s); 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Id) are those, wherein 
     X d  represents a —NR 1d R 2d  moiety or a —OR 3d  moiety; 
     R 1d  represents an alkyl radical selected from the group consisting of —CH 2 —CH 2 —OH and —CH 2 —CH 2 —CH 2 —OH; 
     an unsubstituted adamantyl radical; 
     an unsubstituted phenyl or pyrrolyl radical; 
     an unsubstituted napthyl radical which is bonded via an alkylene group selected form the group consisting of —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 — and —CH 2 —CH 2 —O—; 
     a phenyl radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, tert-butyl, methoxy, F and Cl and said phenyl radical is bonded via an alkylene group selected form the group consisting of —CH 2 —, —CH(CH 3 )—, —CH(Phenyl)-, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 — and —CH 2 —CH 2 —O—; 
     a heteroaryl radical selected from the group consisting of pyridinyl, furanyl and pyrrolyl, whereby said pyridinyl, furanyl or pyrrolyl radical may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, tert-butyl, methoxy, F and Cl and said pyridinyl, furanyl or pyrrolyl radical is bonded via an alkylene group selected form the group consisting of —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 — and —CH 2 —CH 2 —O—; 
     or a —C(═O)—R 12d  moiety; 
     R 2d  represents a hydrogen atom or a methyl radical; 
     or 
     R 1d  and R 2d  together with the bridging nitrogen atom form a moiety selected from the group consisting of: 
     
       
         
         
             
             
         
       
     
     R 3d  represents an unsubstituted phenyl radical; 
     R 4d , R 5d  and R 6d , identical or different, each represent a hydrogen atom or a fluorine atom; 
     or 
     R 4d  and R 5d  together with the bridging carbon atoms form the following moiety, 
     
       
         
         
             
             
         
       
     
     which together with the phenyl ring which it is fused with forms the following substituted bicyclic aromatic ring system 
     
       
         
         
             
             
         
       
     
     R 7d  and R 8d  each represent a hydrogen atom; 
     R 9d  and R 10d , identical or different, each represent a hydrogen atom or a methyl radical; 
     R 11d  represents a hydrogen atom; 
     an alkyl radical selected from the group consisting of methyl, n-butyl and —CH 2 —CH 2 —OH; 
     an unsubstituted phenyl or pyridinyl radical whereby said phenyl or pyridinyl radical may be bonded via a —(CH 2 )— group; 
     a —C(═O)—R 12d  moiety or a —S(═O) 2 —R 13d  moiety; 
     R 12d  represents a phenyl or a thiophenyl radical whereby said phenyl or thiophenyl radical may be substituted with 1, 2 or 3 substituent(s) selected from the group consisting of methyl and chlorine; 
     R 13d  represents a methyl radical or a phenyl or a thiophenyl radical whereby said phenyl or thiophenyl radical may be substituted with 1, 2 or 3 substituent(s) selected from the group consisting of methyl and chlorine 
     and 
     R 14d  represents a methyl radical or a phenyl radical which may be substituted with 1, 2 or 3 methyl radical(s); 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (Id) are those selected from the group consisting of:
         [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-(2-pyrrol-1-yl-ethyl)-amine,   (4-Fluoro-benzyl)-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   N-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-benzamide,   N-Methyl-N-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-benzamide,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-pyrrol-1-yl-amine,   2-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-2H-pyridazin-3-one,   1-Methyl-4-(4-nitro-3-phenoxy-phenyl)-piperazine,   Benzyl-[5-(4-butyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   Benzyl-[2-nitro-5-(4-pyridin-2-yl-piperazin-1-yl)-phenyl]-amine and   Benzyl-[2-nitro-5-(4-phenyl-2-yl-piperazin-1-yl)-phenyl]-amine;   Furan-2-ylmethy-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   2-[4-(4-nitro-3-phenethylamino-phenyl)-piperazin-1-yl]-ethanol,   (2-nitro-5-piperazin-1-yl-phenyl)-(2-o-tolyloxy-ethyl)-amine   2-[4-(3-Benzylamino-4-nitro-phenyl)-piperazin-1-yl]-ethanol,   4-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine,   2-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-4-phenyl-2H-phthalazin-1-one,   [2-(4-chloro-phenoxy)-ethyl]-[5-(3,5-dimethyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   2-[4-[3-(Benzhydryl-amino)-4-nitro-phenyl]-piperazin-1-yl]-ethanol,   4-[4-Fluoro-5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-morpholine,   2-[2-nitro-5-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-phenyl]-1,2,3,4-tetrahydro-isoquinoline,   1-[3-(3,5-Dimethyl-pyrazol-1-yl)-4-nitro-phenyl]-4-methyl-piperazine,   Benzyl-(2-nitro-5-piperazin-1-yl-phenyl)-amine,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-phenethyl-amine,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-pyridin-3-ylmethyl-amine,   (3-chloro-phenyl)-[4-[3-[(furanyl-2-ylmethyl)-amino]-4-nitro-phenyl]-piperazin-1-yl]-methanone,   (2-nitro-5-piperazin-1-yl-phenyl)-pyridin-3-ylmethyl-amine,   1-Benzyl-4-(2-nitro-5-piperazin-1-yl-phenyl)-piperazine,   Furan-2-ylmethyl-[5-(4-methanesulfonyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   Benzhydryl-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   (2-nitro-5-piperazin-1-yl-phenyl)-(2-phenoxy-ethyl)amine,   2-[5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-4-phenyl-2H-phthalazin-1-one,   1-[3-(3,5-Dimethyl-pyrazol-1-yl)-4-nitro-phenyl]-piperazine,   (2-nitro-5-piperazin-1-yl-phenyl)-phenethyl-amine,   [5-(4-Benzenesulfonyl-piperazin-1-yl)-2-nitro-phenyl]-furan-2-ylmethyl-amine,   [2-(3,4-Dimethoxy-phenyl)-ethyl]-(2-nitro-5-piperazin-1-yl-phenyl)-amine,   [4-[3-[(Furan-2-ylmethyl)-amino]-4-nitro-phenyl]-piperazin-1-yl]-m-tolyl-methanone,   [4-[3-[(Furan-2-ylmethyl)-amino]-4-nitro-phenyl]-piperazin-1-yl]-phenyl-methanone,   [4-[3-(3,5-Dimethyl-pyrazol-1-yl)-4-nitro-phenyl]-piperazin-1-yl]-thiophen-2-yl-methanone,   4-(4-Ethyl-phenyl)-2-[5-[4-methyl-piperazin-1-yl)-2-nitro-phenyl]-2H-phthalalazin-1-one,   3-[7-(4-Methyl-piperazin-1-yl)-4-nitro-benzo[1,2,5]oxadiazol-5-ylamino]-propan-1-ol,   3-[4-nitro-7-(4-phenyl-piperazin-1-yl)-benzo[1,2,5]oxadiazol-5-ylamino]-ethan-1-ol,   3-[4-nitro-7-(4-pyridin-piperazin-1-yl)-benzo[1,2,5]oxadiazol-5-ylamino]-propan-1-ol,   [2-(3,4-Dimethoxy-phenyl)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [2-(3,4-Dimethyl-phenyl)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [2-(4-tert-Butyl-phenoxy)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [2-(4-Methoxy-phenoxy)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-(2-m-tolyloxy-ethyl)-amine,   [2-(4-chloro-phenoxy)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   (2-nitro-5-piperazin-1-yl-phenyl)-(1-phenyl-ethyl)-amine,   [2-(3-Methoxy-phenoxy)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [2-(2-Methoxy-phenoxy)-ethyl]-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   (4-chloro-benzyl)-(2-nitro-5-piperazin-1-yl-phenyl)-amine,   Benzyl-[5-(4-benzyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   Benzyl-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-(2-o-tolyloxy-ethyl)-amine,   (4-chloro-benzyl)-[5-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine,   Furan-2-ylmethyl-(2-nitro-5-piperazin-1-yl-phenyl)amine,   [2-(4-chloro-phenoxy)-ethyl]-(2-nitro-5-piperazin-1-yl-phenyl)-amine,   [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-(1-phenyl-ethyl)-amine   1-[4-(3-Benzylamino-4-nitro-phenyl)-piperazin-1-yl]-ethanone,   2-[4-[3-(4-Methylpiperazin-1-yl)-4-nitrophenyl]piperazin-1-yl]ethanol,   2-[4-[3-[2-(Naphthalen-2-yloxy)ethylamino]-4-nitrophenyl]piperazin-1-yl]ethanol,   2-[4-(3-{[1-(1-Adamantyl)ethyl]amino}-4-nitrophenyl)piperazin-1-yl]ethanol and   2-[4-[3-(3,4-Dimethoxyphenethylamino)-4-nitrophenyl]piperazin-1-yl]ethanol;       

     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     The compounds of general formula Id are prepared by a process, wherein at least one nitrobenzene compound of general formula II, 
     
       
         
         
             
             
         
       
     
     wherein R 4d  to R 6d  have any of the above given meanings, Y d  represents a chlorine atom, and Z d  represents a bromine or iodine atom; is reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 7d  to R 11d  have any of the above given meanings in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of tetrahydrofuran, toluene and dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of PdCl 2 (dppf) wherein dppf is 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one auxiliary agent, preferably 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one base, preferably sodium tert-pentoxide, to yield a compound of general formula IV, 
     
       
         
         
             
             
         
       
     
     wherein R 4d  to R 11d  have any of the above given meanings and Y d  represents a chlorine atom; which is optionally purified and/or isolated, and the compound of general formula IV is reacted with at least one compound of general formula V, 
     
       
         
         
             
             
         
       
     
     wherein R 1d  and R 2d  have any of the above given meanings, in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of toluene or dimethoxyethane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least a palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and/or at least one auxiliary agent, preferably (biph)P(tBu) 2 , wherein biph is biphenyl and tBu is tert-butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4  and sodium tert-pentoxide to yield a compound of general formula VI, 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 2d  and R 4d  to R 11d  have any of the above given meanings which is optionally purified and/or isolated. 
     The compounds of general formula Id are prepared by a process, wherein at least one nitrobenzene compound of general formula VII, 
     
       
         
         
             
             
         
       
     
     wherein R 4d  to R 6d  have any of the above given meanings, Z d  represents a bromine or iodine atom, and Y d  represents a chlorine atom, is reacted with at least one compound of general formula V, 
     
       
         
         
             
             
         
       
     
     wherein R 1d  and R 2d  have any of the above given meanings in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of toluene and dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium and/or copper source, even more preferably in the presence of at least a palladium and/or copper source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and copper(I)iodide, and/or at least one auxiliary agent, preferably at least one auxiliary agent selected from the group consisting of 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 1,1-bis(diphenylphosphino-ferrocene and P(tBu) 3 , wherein tBu is tert-Butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4 , Cs 2 CO 3  and trans-1,2-diamino-methylcyclohexane, to yield a compound of general formula VIII, 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 2d  and R 4d  to R 6d  have any of the above given meanings and Y d  represents a chlorine atom; which is optionally purified and/or isolated, and the compound of general formula VIII is reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 7d  to R 11d  have any of the above given meanings, in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of toluene, tetrahydrofuran and dimethoxyethane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least a palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and/or at least one auxiliary agent, preferably (biph)P(tBu) 2 , wherein biph is biphenyl and tBu is tert-butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4  or sodium tert-pentoxide, to yield a compound of general formula VI, 
     
       
         
         
             
             
         
       
     
     wherein R 1d , R 2d  and R 4d  to R 11d  have any of the above given meanings, which is optionally purified and/or isolated. 
     The compounds of general formula Id are prepared by a process, wherein at least one nitrobenzene compound of general formula II, 
     
       
         
         
             
             
         
       
     
     wherein R 4d  to R 6d  have any of the above given meanings, Y d  represents a chlorine atom, and Z d  represents a bromine or iodine atom; is reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 7d  to R 11d  have any of the above given meanings, in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of tetrahydrofuran or dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of PdCl 2 (dppf), wherein dppf is 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one auxiliary agent, preferably 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one base, preferably sodium tert-pentoxide, to yield a compound of general formula IV, 
     
       
         
         
             
             
         
       
     
     wherein R 4d  to R 11d  have any of the above given meanings and Y d  represents a chlorine atom; which is optionally purified and/or isolated, and the compound of general formula IV is reacted with at least one compound of general formula IX, 
     
       
         
         
             
             
         
       
     
     wherein R 3d  has any of the above given meanings, in a suitable reaction medium, preferably in at least an organic solvent, more preferably in at least an organic solvent selected from the group consisting of toluene or dimethoxyethane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least a palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and/or at least one auxiliary agent, preferably (biph)P(tBu) 2 , wherein biph is biphenyl and tBu is tert-butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4  and sodium tert-pentoxide to yield a compound of general formula X, 
     
       
         
         
             
             
         
       
     
     wherein R 3d  to R 11d  have any of the above given meanings, which is optionally purified and/or isolated. 
     Suitable reaction media include organic solvents, such as dialkyl ether, preferably diethyl ether and dimethoxyethane, or a cyclic ether, preferably tetrahydrofuran or dioxane; or a halogenated hydrocarbon, preferably dichloromethane or chloroform; an alcohol, preferably methanol or ethanol; an aprotic solvent, preferably acetonitrile, toluene, pyridine or dimethylformamide, or any other suitable reaction medium. Of course, mixtures of at least two classes of solvents or of at least two solvents of one class may also be used. 
     All of above mentioned reactions are preferably carried out in an oven-dried vial. The catalyst, the auxiliary agent, the base and the compound of general formula II, IV, VII or VIII are added in each case and the vial is subsequently evacuated and purged with argon. The organic solvent and the compound of general formula III, V or IX are added and the reaction is carried out in a sealed vial at a temperature between 100° C. and 110° C., preferably at 100° C. in case of tetrahydrofuran or toluene as the organic solvent and at 110° C. in case of dimethoxyethane and dioxane as the organic solvent. 
     Suitable reaction conditions for carrying out the reaction between compounds of general formula II, IV, VII or VIII and compounds of general formula III, V or IX are described in the references of J. F. Hartwig et al., J. Am. Chem. Soc. 1996, 118, 7217-7218; S. L. Buchwald et al., J. Am. Chem. Soc. 2002, 124, 6043-6048; S. L. Buchwald et al. J. Am. Chem. Soc. 2002, 124, 7241-7424 and S. L. Buchwald et al., J. Am. Chem. Soc. 2002, 124, 11684-11688. The respective part of the description is hereby incorporated by reference and forms part of the present disclosure. 
     The compounds of general formulas IV, VI, VIII and X given above may be purified and/or isolated according to methods well known to those skilled in the art. 
     The compounds of general formulas IV, VI, VIII and X may be isolated by evaporating the reaction medium, addition of water and adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purification by chromatography or recrystallisation from a suitable solvent. 
     Preferably, the compounds of general formula IV, VI, VIII and X may be obtained by filtration of the reaction mixture and subsequent separation of the reaction mixture on a TLC plate. Alternatively, the compounds of general formula I may be isolated by addition of water and methanol to the reaction mixture, evaporating the reaction mixture and purifying the residue by preparative HPLC. 
     The compounds of general formula II and VII are commercially available or may be prepared according to methods well known in the art, for example, analogous to the methods described in the bibliography of A. McKillop et al., Tetrahedron 1987, 43, 1753. The respective part of the literature description cited above is hereby incorporated by reference and forms part of the disclosure. 
     The compounds of general formula III, V and IX are commercially available or may be prepared according to methods well known in the art. 
     During some synthetic reactions described above or while preparing the compounds of general formulas III, V, VI, IX or X the protection of sensitive or reactive groups may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T. W. Greene &amp; P. G. M. Wuts and Protective Groups in Organic Chemistry, John Wiley &amp; sons, 1991. The respective parts of the description is hereby incorporated by reference and forms part of the disclosure. The protective groups may be eliminated when convenient by means well-known to those skilled in the art. 
     If the nitro-substituted phenyl-piperazine compounds of general formula Id are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents. 
     The nitro-substituted phenyl-piperazine compounds of general formula Id and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of phenyl-piperazine-derived compounds of general formula (Ie) 
     
       
         
         
             
             
         
       
     
     wherein 
     X e  represents —CN, —C(═O)—OH, —C(═O)—OR 4e , —O—R 5e , —NH 2 , —NR 6e —C(═O)—R 7e , —NH—S(═O) 2 —R 8e  or —NH—R 9e ; 
     R 1e  represents a hydrogen atom; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group which may contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as chain member(s); 
     R 2e  represents a hydrogen atom or a —C(═O)—R 10e  moiety; 
     or 
     R 1e  and R 2e  together with the bridging nitrogen form a nitro (NO 2 )— group or 
     an unsubstituted or at least mono-substituted 5- or 6-membered heteroaryl radical which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 3e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 4e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 5e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     R 6e  represents a hydrogen atom or 
     an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     R 7e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 8e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     R 9e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     and 
     R 10e  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Preferred compounds of general formula (Ie) are those, wherein 
     X e  represents —CN, —C(═O)—OH, —C(═O)—OR 4e , —O—R 5e , —NH 2 , —NR 6e —C(═O)—R 7e , —NH—S(═O) 2 —R 8e  or —NH—R 9e ; 
     R 1e  represents 
     a hydrogen atom; or 
     an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, furyl(furanyl) and thiophenyl(thiophenyl), whereby said aryl or heteroaryl radical is bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )—, —(CH 2 )—(CH 2 )—(CH 2 )—, —O—(CH 2 )—(CH 2 )—, or —(CH 2 )— (CH 2 )—O— group and/or may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , F, Cl, Br, —CN, —CF 3 , —OCF 3 , —OH and —SH. 
     R 2  represents a hydrogen atom or a —C(═O)—R 10  moiety; 
     R 1e  and R 2e  together with the bridging nitrogen atom form a nitro group or moiety selected from the group consisting of 
     
       
         
         
             
             
         
       
     
     whereby each of these afore mentioned cyclic moieties may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, F, Cl, Br, I, —CN and —CF 3 , 
     R 3e  represents a methyl or ethyl radical; 
     R 4e  represents a methyl or ethyl radical; 
     R 5e  represents 
     an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     or an aryl or heteroaryl radical selected from the group consisting of phenyl, naphthyl, furyl(furanyl) and thiophenyl(thiophenyl), whereby said aryl or heteroaryl radical is bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )— or —(CH 2 )—(CH 2 )—(CH 2 )— group and/or may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , F, Cl, Br, —CN, —CF 3 , —OCF 3 , —OH and —SH; 
     R 6e  represents a hydrogen atom, or 
     a phenyl radical, whereby said phenyl radical may be bonded via a —(CH 2 )— group and/or may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br, —CF 3 , —OCF 3 , —OH and —SH; 
     R 7e  represents a methyl or ethyl radical; 
     R 8e  represents 
     an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; or 
     an aryl radical selected from the group consisting of phenyl and naphthyl, whereby said aryl radical may be bonded via a —(CH 2 )—, or —(CH 2 )—(CH 2 )— group and/or may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , F, Cl, Br, —CN, —CF 3 , —OCF 3 , —OH and —SH, 
     R 9e  represents 
     an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     or an aryl radical selected from the group consisting of phenyl and naphthyl, whereby said aryl radical may be bonded via a —(CH 2 )—, —(CH 2 )—(CH 2 )— or —(CH 2 )—(CH 2 )—(CH 2 )— group and/or may be unsubstituted or substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , F, Cl, Br, —CN, —CF 3 , —OCF 3 , —OH and —SH; 
     R 10e  represents a methyl or ethyl radical; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, respectively. 
     Particularly preferred compounds of general formula (Ie) are those selected from the group consisting of:
         4-(4-Methyl-piperazin-1-yl)-2-phenethylamino-benzoic acid,   2-[(Furan-2-ylmethyl)-amino]-4-(4-methyl-piperazin-1-yl)-benzonitrile,   2-[(Furan-2-ylmethyl)-amino]-4-(4-methyl-piperazin-1-yl)-benzoic acid,   2-Benzylamino-4-(4-methyl-piperazin-1-yl)-benzoic acid methyl ester,   2-Benzylamino-4-(4-methyl-piperazin-1-yl)-benzonitrile,   4-(4-Methyl-piperazin-1-yl)-2-phenethylamino-benzoic acid methyl ester,   2-[(Furan-2-ylmethyl)-amino]-4-(4-methyl-piperazin-1-yl)-benzoic acid methyl ester,   2-Benzylamino-4-(4-methyl-piperazin-1-yl)-benzoic acid,   [2-Benzyloxy-5-(4-methyl-piperazin-1-yl)-phenyl]-phenethyl-amine,   [2-Benzyloxy-5-(4-methyl-piperazin-1-yl)-phenyl]-furan-2-yl-methyl amine,   Benzyl-[2-methoxy-5-(4-methyl-piperazin-1-yl)-phenyl]-amine,   [2-Methoxy-5-(4-methyl-piperazin-1-yl)-phenyl]-phenethyl-amine,   Furan-2-ylmethy-[2-methoxy-5-(4-methyl-piperazin-1-yl)-phenyl]-amine,   Benzyl-[2-benzyloxy-5-(4-methyl-piperazin-1-yl)-phenyl]-amine,   N-[2-Acetyl-(2-phenoxyethyl)-amino]-4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide,   N-[4-(4-Methyl-piperazin-1-yl)-2-(2-phenoxy-ethylamino)-phenyl]-acetamide,   N-[2-(Acetyl-amino)-4-(4-methyl-piperazin-1-yl)-phenyl]-N-benzyl-acetamide,   N-[2-(3,5-Dimethyl-pyrazol-1-yl)-4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide,   N-[2-(Acetyl-furan-2-ylmethyl-amino)-4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide,   N-[2-Benzylamino-4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide,   N-[2-[Furan-2-ylmethyl)-amino]-4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide,   N-[2-Amino-5-(4-methyl-piperazin-1-yl)-phenyl]-N-furan-2-ylmethyl-acetamide,   N-[2-Amino-4-(4-methyl-piperazin-1-yl)-phenyl]-N-benzyl-acetamide,   N-[2-Benzylamino-4-(4-methyl-piperazin-1-yl)-phenyl]-benzenesulfonamide,   N-[2-Benzylamino-4-(4-methyl-piperazin-1-yl)-phenyl]-methansulfonamide,   2-Benzyloxy-5-(4-methyl-piperazin-1-yl)-phenylamine,   Benzyl-[4-(4-methyl-piperazin-1-yl)-2-nitro-phenyl]-amine and   2-Cyano-(5-piperazin-1-yl-methyl)-2-phenoxy-ethylamine       

     optionally in form of one of their stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof. 
     The compounds of general formula Ie are prepared by a process, wherein at least one substituted benzene compound of general formula II, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═O)—OR 4e , —O—R 5e  or —NO 2 , R 4e  and R 5e  have any of the above given meanings, Y e  represents a chlorine atom, and Z e  represents a bromine or iodine atom; is reacted with at least one piperazine compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  has any of the above given meanings, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of tetrahydrofuran, toluene or dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least one palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and PdCl 2 (dppf), wherein dppf is 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one auxiliary agent, preferably at least one auxiliary agent selected from the group consisting of 1,1-bis(diphenylphosphino)-ferrocene and 2,2′-bis(diphenylphosphino)-1′1-binaphthyl (BINAP), optionally in form of its enantiomers or a racemate, and/or at least one base, preferably at least one base selected from the group consisting of sodium tert-pentoxide and Cs 2 CO 3  to yield a compound of general formula IV, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═)—OR 4e , —O—R 5e  or —NO 2 , R 3e , R 4e  and R 5e  have and of the above given meanings and Y e  presents a chlorine atom; which is optionally purified and/or isolated, and the compound of general formula IV is reacted with at least one compound of general formula V, 
     
       
         
         
             
             
         
       
     
     wherein R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of toluene, dioxane and dimethoxyethane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least a palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and/or at least one auxiliary agent, preferably at least one auxiliary agent selected from the group consisting of (biph)P(tBu) 2 , wherein biph is biphenyl and tBu is tert-butyl, and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), and and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4 , Cs 2 CO 3  and sodium tert-pentoxide to yield a compound of general formula VI, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═O)—OR 4e , —O—R 5e  or —NO 2 , R 1e , R 2e  have any of the above given meanings or one of them represents a protecting group, preferably —C(═O)—O—C(CH 3 ) 3  and R 3e , R 4e  and R 5e  have any of the above given meanings, said compound of general formula VI is being optionally purified and/or isolated, 
     or at least one substituted benzene compound of general formula IIa, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═O)—OR 4e , —O—R 5e  or —NO 2 , R 4e  and R 5e  have any of the above given meanings, Z e  represents a chlorine atom, Y e  represents a bromine or iodine atom, is reacted with at least one compound of general formula V, 
     
       
         
         
             
             
         
       
     
     wherein R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of toluene, dimethoxyethane and dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium and/or copper source, even more preferably in the presence of at least a palladium and/or copper source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, Pd 2 dba 3 , wherein dba is dibenzylidene acetone, and copper(I)iodide, and/or at least one auxiliary agent, preferably at least an auxiliary agent selected from the group consisting of 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 1,1-bis(diphenylphosphino-ferrocene and P(tBu) 3  wherein tBu is tert-Butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4 , Cs 2 CO 3  and trans-1,2-diamino-methylcyclohexane to yield a compound of general formula VII, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═O)—OR 4e , —O—R 5e  or —NO 2 , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group, R 4e  and R 5e  have any of the above given meanings, and Y represents a chlorine atom; said compound of general formula being optionally purified and/or isolated, and the compound of general formula VII is reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  has any of the above given meanings, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of tetrahydrofuran, toluene or dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least one palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and PdCl 2 (dppf), wherein dppf is 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one auxiliary agent, preferably at least one auxiliary agent selected from the group consisting of 1,1-bis(diphenylphosphino)-ferrocene and 2,2′-bis(diphenylphosphino)-1′1-binaphthyl (BINAP), optionally in form of its enantiomers or a racemate, and/or at least one base, preferably at least one base selected from the group consisting of sodium tert-pentoxide and Cs 2 CO 3 , to yield a compound of general formula VI, 
     
       
         
         
             
             
         
       
     
     wherein X e  represents —CN, —C(═O)—OR 4e , —O—R 5e  or —NO 2 , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group, and R 3e , R 4e  and R 5e  have any of the above given meanings, and said compound of general formula VI is optionally purified and/or isolated, 
     or 
     at least one substituted benzene compound of general formula VIII, 
     
       
         
         
             
             
         
       
     
     wherein Z e  represents bromine or iodine and Y e  represents chlorine, is reacted with at least one compound of general formula IX, 
     
       
         
         
             
             
         
       
     
     wherein R 6e  has any of the above given meanings and PG represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of toluene and dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium and/or copper source, even more preferably in the presence of at least a palladium and/or copper source selected from the group consisting of Pd(OAc) 2  wherein OAc is acetate, Pd 2 dba 3  wherein dba is dibenzylidene acetone and copper(I)iodide, and/or at least one auxiliary agent, preferably at least an auxiliary agent selected from the group consisting of 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 1,1-bis(diphenylphosphino-ferrocene and P(tBu) 3  wherein tBu is tert-Butyl, and/or at least one base, preferably at least one base selected from the group consisting of K 3 PO 4 , Cs 2 CO 3  and trans-1,2-diamino-methylcyclohexane to yield a compound of general formula XI, 
     
       
         
         
             
             
         
       
     
     wherein R 6e  has any of the above given meanings, PG represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group and Y e  represents chlorine; which is optionally purified and/or isolated, and the compound of general formula XI reacted with at least one compound of general formula III, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  has any of the above given meanings, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of tetrahydrofuran, toluene or dioxane, preferably in the presence of at least one catalyst, more preferably in the presence of at least a palladium source, even more preferably in the presence of at least one palladium source selected from the group consisting of Pd(OAc) 2 , wherein OAc is acetate, and PdCl 2 (dppf), wherein dppf is 1,1-bis(diphenylphosphino)-ferrocene, and/or at least one auxiliary agent, preferably at least one auxiliary agent selected from the group consisting of 1,1-bis(diphenylphosphino)-ferrocene and 2,2′-bis(diphenylphosphino)-1′1-binaphthyl (BINAP), optionally in form of its enantiomers or a racemate, and/or at least one base, preferably at least one base selected from the group consisting of sodium tert-pentoxide and Cs 2 CO 3 , to yield a compound of general formula XII, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  and R 6e  have any of the above given meanings and PG represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3  group, which is optionally purified and/or isolated, and the compound of general formula XII is reacted with at least one acid in a suitable reaction medium to yield a compound of general formula XIII, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  and R 6e  have any of the above given meanings, which is optionally purified and/or isolated, and the compound of general formula is reacted with hydrogen in the presence of at least one catalyst, preferably in the presence of at least one palladium source, more preferably in the presence of palladium on charcoal, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in an organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula XIV, 
     
       
         
         
             
             
         
       
     
     wherein R 3e  and R 6e  have any of the above given meanings, which is optionally purified and/or isolated, and the compound of general formula XIV is reacted with at least one compound of general formula R 7e —C(═O)—O—C(═O)—R 7e , wherein R 7e  any of the above given meanings, and/or at least one compound of general formula R 10e —C(═O)—O—C(═O)—R 10e , wherein R 10e  has any of the above given meanings, optionally in the presence of at least one base, preferably in the presence of at least one organic base, more preferably in the presence of at least an organic base selected from the group consisting of pyridine, triethylamine and diisopropylethylamine, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula I, wherein X e  represents —NR 6e —C(═O)R 7e , R 1e  represents a hydrogen atom, R 2e  represents a hydrogen atom or a —C(═O)—R 10e -moiety and R 3e , R 6e , R 7e  and R 10e  have any of the above given meanings, which is optionally purified and/or isolated, 
     and/or at least one compound of general formula VI, wherein X e  represents —CN, —C(═O)—OR 4e  or —O—R 5e , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3 — group, R 3e , R 4e  and R 5e  have any of the above given meanings, is reacted with at least one acid, preferably at least one acid selected from the group consisting of sulfuric acid, hydrochloric acid and acetic acid, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane and tetrahydrofuran, to yield a compound of general formula I, wherein X e  represents —CN, —C(═O)—OR 4e  or —O—R 5e , R 1e  and R 3e  to R 5e  have any of the above given meanings and R 2e  represents hydrogen, which is optionally purified and/or isolated, 
     and optionally at least one compound of general formula I, wherein X e  represents —CN, —C(═O)—OR 4e  or —O—R 5e , R 1e  and R 3e  to R 5e  have any of the above given meanings and R 2e  represents hydrogen, is reacted with hydrogen in the presence of at least one catalyst, preferably in the presence of at least one palladium source, more preferably in the presence of palladium on charcoal, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in an organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula I, wherein X e  represents —CN, —C(═O)—OR 4e  or —O—R 5e , R 3e  to R 5e  have any of the above given meanings and R 1e  and R 2e  each represent hydrogen, 
     at least one compound of general formula VI, wherein X e  represents —C(═O)—OR 4e , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3 — group, R 3e  and R 4e  have any of the above given meanings, is reacted with at least one base, preferably at least one metal hydroxide, more preferably at least one metal hydroxide selected from the group consisting of lithium hydroxide and potassium hydroxide, in a suitable reaction medium, preferably in a mixture of at least one organic solvent and water, more preferably in a mixture of at least one organic solvent selected from the group consisting of dioxane, ethanol and methanol and water, to yield a compound of general formula XV, wherein X e  represents —C(═O)—OH, R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3 — group, R 3e  has any of the above given meanings, which is optionally purified and/or isolated and at least one compound of general formula XV is reacted with at least one acid, preferably at least one acid selected from the group consisting of sulfuric acid, hydrochloric acid and acetic acid, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane and tetrahydrofuran, to yield a compound of general formula I, wherein X e  represents —C(═O)—OH, R 1e  and R 3e  have any of the above given meanings and R 2e  represents hydrogen, which is optionally purified and/or isolated, 
     and/or 
     at least one compound of general formula VI, wherein X e  represents —NO 2 , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3 — group and R 3e  has any of the above given meanings, is reacted with hydrogen in the presence of at least one catalyst, preferably in the presence of at least one palladium source, more preferably in the presence of palladium on charcoal, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in an organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula XVI, wherein X e  represents —NH 2 , R 1e  and R 2e  have any of the above given meanings or one of them represents a protecting group, preferably a —C(═O)—O—C(CH 3 ) 3 — group, and R 3e  has any of the above given meanings, which is optionally purified and/or isolated, and at least one compound of general formula XVI, is reacted with at least one acid, preferably at least one acid selected from the group consisting of sulfuric acid, hydrochloric acid and acetic acid, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane and tetrahydrofuran, to yield a compound of general formula I, wherein X e  represents —NH 2 , R 1e  and R 3e  have any of the above given meanings and R 2e  represents hydrogen, which is optionally purified and/or isolated, 
     and optionally at least one compound of general formula I, wherein X e  represents —NH 2 , R 1e  and R 3e  have any of the above given meanings and R 2e  represents hydrogen, is reacted with at least one compound of general formula R 7e —C(═O)—O—C(═O)—R 7e  and/or at least one compound of general formula R 10e —C(═O)—O—C(═O)—R 10e , wherein R 7e  and R 10e  have any of the above given meanings optionally in the presence of at least one base, preferably in the presence of at least one organic base, more preferably in the presence of at least an organic base selected from the group consisting of pyridine, triethylamine and diisopropylethylamine, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula I, wherein X e  represents —NH—C(═O)—R 7e  and R 1e  to R 3e  have any of the above given meanings, which is optionally purified and/or isolated, 
     and/or optionally at least one compound of general formula I, wherein X e  represents —NH 2  and R 1e  and R 3e  have any of the above given meanings and R 2e  e represents hydrogen, is reacted with at least one compound of general formula R 8e —S(═O)—W, wherein R 8e  has any of the above given meanings and W represents a halogen atom, preferably a chlorine atom, optionally in the presence of at least one base, preferably in the presence of at least one organic base, more preferably in the presence of an organic base selected from the group consisting of pyridine, triethylamine and diisopropylethylamine, in a suitable reaction medium, preferably in at least one organic solvent, more preferably in at least one organic solvent selected from the group consisting of dioxane, tetrahydrofuran and diethyl ether, to yield a compound of general formula I, wherein X e  represents —NH—S(═O) 2 —R 8e  and R 1e , R 3e  and R 8e  have any of the above given meanings and R 2e  represents hydrogen, which is optionally purified and/or isolated. 
     Suitable reaction media include organic solvents, such as dialkyl ether, preferably diethyl ether and dimethoxyethane, or a cyclic ether, preferably tetrahydrofuran or dioxane; or a halogenated hydrocarbon, preferably dichloromethane or chloroform; an alcohol, preferably methanol or ethanol; an aprotic solvent, preferably acetonitrile, pyridine, toluene or dimethylformamide, or any other suitable reaction medium. Of course, mixtures of at least two classes of solvents or of at least two solvents of one class may also be used. 
     If the above mentioned reactions are carried out in an oven-dried vial, the catalyst, the auxiliary agent, the base and the compound of general formula II, IIa, IV, VII, VIII or XI are added in each case and the vial is subsequently evacuated and purged with argon. The organic solvent and the compound of general formula III, V and IX are added and the reaction is carried out in a sealed vial at a temperature between 100° C. and 110° C., preferably at 100° C. in case of tetrahydrofuran or toluene as the organic solvent and at 110° C. in case of dimethoxyethane and dioxane as the organic solvent. 
     Suitable reaction conditions for carrying out the reaction between compounds of general formula II, IIa, IV, VII, VIII or XI and compounds of general formula III, V and IX are described in the references of J. F. Hartwig et al., J. Am. Chem. Soc. 1996, 118, 7217-7218; S. L. Buchwald et al., J. Org. Chem. 2000, 65, 1144-1157; S. L. Buchwald et al., J. Am. Chem. Soc. 2002, 124, 6043-6048; S. L. Buchwald et al. J. Am. Chem. Soc. 2002, 124, 7241-7424 and S. L. Buchwald et al., J. Am. Chem. Soc. 2002, 124, 11684-11688. The respective part of the description is hereby incorporated by reference and forms part of the present disclosure. 
     The compounds of general formula I, IV, VI, VII, XI, XII, XIII, XIV, XV and XVI may be isolated by evaporating the reaction medium, addition of water and adjusting the pH value to obtain the compound in form of a solid that can be isolated by filtration, or by extraction with a solvent that is not miscible with water such as chloroform and purification by chromatography or recrystallisation from a suitable solvent. 
     Preferably, the compounds of general formula I, IV, VI, VII, XI, XII, XIII, XIV, XV and XVI may be obtained by filtration of the reaction mixture and subsequent separation of the reaction mixture on a TLC plate. Alternatively, the compounds of general formula I, IV, VI, VII, XI, XII, XIII, XIV, XV and XVI may be isolated by addition of water and methanol to the reaction mixture, evaporating the reaction mixture and purifying the residue by preparative HPLC. 
     The compounds of general formula II, IIa, VIII and IX are commercially available or may be prepared according to methods well known in the art, for example, analogous to the methods described in the bibliography of A. McKillop et al., Tetrahedron 1987, 43, 1753. The respective part of the literature description cited above is hereby incorporated by reference and forms part of the disclosure. 
     During some synthetic reactions described above or while preparing the compounds of general formulas II, IIa, VIII and IX the protection of sensitive or reactive groups may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T. W. Greene &amp; P. G. M. Wuts and Protective Groups in Organic Chemistry, John Wiley &amp; sons, 1991. The respective parts of the description is hereby incorporated by reference and forms part of the disclosure. The protective groups may be eliminated when convenient by means well-known to those skilled in the art. 
     If the substituted phenyl-piperazine compounds of general formula Ie are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents. 
     The substituted phenyl-piperazine compounds of general formula Ie and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. 
     Preferably as component (A) at least one compound is present which is selected from the group consisting of tetrahydroisoquinoline-derived sulfonamide compounds of general formula (If) 
     
       
         
         
             
             
         
       
     
     wherein 
     R 1f  represents a hydrogen atom; a —C(═O)—OR 37f  moiety; 
     a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     R 2f , R 3f , R 4f  and R 5f , independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O) 2 —OH; —C(═O)—NH 2 ; —S(═O) 2 —NH 2 ; —C(═O)—R 8f ; —S(═O)—R 7f ; —S(═O) 2 —R 7f ; —OR 8f ; —SR 9f ; —C(═O)—OR 10f ; —N(R 11f )—S(═O) 2 —R 12f ; —NR 13f R 14f ; —NH—R 15f ; —C(═O)—NR 16f R 17f ; C(═O)—NHR 18f ; 
     a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated or unsaturated, but not aromatic, mono- or bicyclic ring system; 
     with the proviso that at least one of the substituents R 2f , R 3f , R 4f  and R 5f  represents a —N(R 11f )—(═O) 2 —R 12f  moiety; 
     R 6f , R 7f , R 8f , R 9f , R 10f , R 13f , R 14f , R 15f , R 16f , R 17f  and R 18f , 
     independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated or unsaturated, but not aromatic, mono- or bicyclic ring system; 
     R 11f  represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     R 12f  represents a phenyl radical of general formula (Af), 
     
       
         
         
             
             
         
       
     
     wherein 
     R 19f , R 20f , R 21f , R 22f  and R 38f , independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O) 2 —OH; —C(═O)—NH 2 ; —S(═O) 2 —NH 2 ; —C(═O)—R 23f ; —S(═O)—R 24f ; —S(═O) 2 —R 24f ; —OR 25f ; —SR 26f ; —C(═O)—OR 27f ; —N(R 28f )—S(═O) 2 —R 29f ; —NH—S(═O) 2 —R 30f ; —NR 31f R 32f ; —NH—R 33f ; —C(═O)—NHR 34f ; —C(═O)—NR 35f R 36f ; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; 
     an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system and/or which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group; 
     or a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     R 23f , R 27f , R 28f , R 29f  and R 30f , independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated or unsaturated, but not aromatic, mono- or bicyclic ring system; 
     R 24f , R 26f , R 31f , R 32f  and R 33f , each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be condensed with an unsubstituted or at least mono-substituted saturated or unsaturated, but not aromatic, mono- or bicyclic ring system; 
     R 25f , R 34f , R 35f  and R 36f , represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     and R 37f  represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; 
     a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated, unsaturated or aromatic mono- or bicyclic ring system; 
     or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene, alkenylene or alkinylene group and which may be condensed with an unsubstituted or at least mono-substituted saturated or unsaturated, but not aromatic, mono- or bicyclic ring system; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, or a corresponding solvate thereof. 
     Preferred compounds of general formula (If) are those, wherein 
     R 1f  represents a hydrogen atom; a —C(═O)—OR 37f  moiety; a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, —CH 2 —NH 2 , —CH 2 —NH—CH 3 , —CH 2 —N(CH 3 ) 2 , —CH 2 —N(C 2 H 5 ) 2 , —CH 2 —NH—C 2 H 5 , —CH 2 —CH 2 —NH 2 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 ) 2 , —CH 2 —CH 2 —N(C 2 H 5 ) 2 , —CH 2 —CH 2 —NH—C 2 H 5 , —CH 2 —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —CH 2 —N(CH 3 ) 2 , —CH 2 —CH 2 —CH 2 —N(C 2 H 5 ) 2  and —CH 2 —CH 2 —CH 2 —NH—C 2 H 5 ; or a (hetero)cycloaliphatic radical selected from the group consisting of imidazolidinyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrazolidinyl and azepanyl, which may be bonded via a —(CH 2 ) 1, 2 or 3 — group and which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl and isobutyl; 
     R 2f , R 3f , R 4f  and R 5f , independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO 2 ; —O—CH 3 ; —O—C 2 H 5 ; —O—CF 3 ; —O—CFH 2 ; —O—CF 2 H; —O—CH 2 —CF 3 ; —O—CF 2 —CF 3 ; —S—CH 3 ; —S—C 2 H 5 ; —S—CF 3 ; —S—CFH 2 ; —S—CF 2 H; —S—CH 2 —CF 3 ; —S—CF 2 —CF 3 ; —N(R 11f )—S(═O) 2 —R 12f ; or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, tert-butyl, —CF 3 , —CFH 2 , —CF 2 H, —CH 2 —CF 3  and —CF 2 —CF 3 ; 
     with the proviso that at least one of the substituents R 2f , R 3f , R 4f  and R 5f  represents a —N(R 11f )—S(═O) 2 —R 12f  moiety; 
     R 11f  represents a hydrogen atom, —S(═O) 2 —R 12f  or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; 
     R 12f  represents a phenyl radical of general formula (Af), 
     
       
         
         
             
             
         
       
     
     wherein 
     R 19f , R 20f , R 21f , R 22f  and R 38f , independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO 2 ; —NH 2 ; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —C(═O)—CH 3 ; —C(═O)—C 2 H 5 ; —O—CH 3 ; —O—C 2 H 5 ; —O—CF 3 ; —O—CFH 2 ; —O—CF 2 H; —O—CH 2 —CF 3 ; —O—CF 2 —CF 3 ; —S—CH 3 ; —S—C 2 H 5 ; —S—CF 3 ; —S—CFH 2 ; —S—CF 2 H; —S—CH 2 —CF 3 ; —S—CF 2 —CF 3 ; —C(═O)—OCH 3 ; —C(═O)—OC 2 H 5 ; methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, —CF 3 , —CF 2 H, —CFH 2 , —CH 2 —CF 3  and —CF 2 —CF 3 ; 
     a radical selected from the group consisting of naphthyl, [1,3]-benzodioxolyl, [1,4]-benzodioxanyl, benzo[b]furanyl, benzo[b]thiophenyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo[2,1-b]thiazolyl, which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, —O—CH 3 , —O—C 2 H 5 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —CF 2 H and —CFH 2 ; 
     or a radical selected from the group consisting of pyridinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl and pyrazinyl, which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of F, Cl, Br, I, —NO 2 ; methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, —CF 3 , —CF 2 H, —CFH 2 , —CH 2 —CF 3  and —CF 2 —CF 3 ; 
     and R 37f  represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, fluorenyl, fluorenylmethyl, phenyl, benzyl and naphthyl; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, or a corresponding solvate thereof. 
     Particularly preferred compounds of general formula (If) are those selected from the group consisting of:
         N-(1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-1-sulfonamide hydrochloride,   2,2-dimethyl-6-(N-methylnaphthalene-1-sulfonamido)-1,2,3,4-tetrahydroisoquinolinium iodide,   N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-1-sulfonamide hydrochloride,   5-chloro-3-methyl-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzo[b]thiophene-2-sulfonamide hydrochloride,   5-chloro-3-methyl-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzo[b]thiophene-2-sulfonamide hydrochloride,   4-methyl-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-1-sulfonamide hydrochloride,   4-methyl-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-1-sulfonamide hydrochloride,   N-(1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-2-sulfonamide hydrochloride,   N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)naphthalene-2-sulfonamide hydrochloride,   6-Chloro-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazo[2,1-b]thiazole-5-sulfonamide hydrochloride,   2-methoxy-5-methyl-N-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide hydrochloride,   N-(1,2,3,4-tetrahydroisoquinolin-6-yl)pyridine-3-sulfonamide dihydrochloride,   6-(naphthalene-1-sulfonylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester,   6-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester,   6-(4-methyl-naphthalene-1-sulfonylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester,   6-(naphthalene-2-sulfonylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester,   6-(2-methoxy-5-methyl-benzenesulfonylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester and       

     6-(pyridine-3-sulfonylamino)-3,4-dihydro-1H-isoquinoline-2carboxylic acid tert-butyl ester; 
     optionally in form of one of its stereoisomers, preferably enantiomers or diasteromers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, or a corresponding solvate thereof. 
     The compounds of general formula If are prepared by a process, wherein at least one compound of general formula IV, 
     
       
         
         
             
             
         
       
     
     wherein R 12f  has the meaning given above and X represents a leaving group, preferably a halogen atom, particularly preferably a chlorine atom, is reacted with at least one compound of general formula V, 
     
       
         
         
             
             
         
       
     
     wherein R 1f  to R 5f  have the meaning given above, with the proviso that at least one substituent of the group consisting of R 2f , R 3f , R 4f  and R 5f  represents a —N(H)(R 11f ) moiety, wherein R 11f  has the meaning given above, or a protected derivative thereof, in a reaction medium, preferably in a reaction medium selected from the group consisting of pyridine, chloroform, dichloromethane, tetrahydrofurane and mixtures thereof, preferably in the presence of at least one base, more preferably in the presence of at least one base selected from the group consisting of triethylamine, diisopropylethylamine and diethylisopropylamine, preferably at a temperature between 0° C. and 30° C. 
     If the substituted tetrahydroisoquinoline compounds of general formula If are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents. 
     The substituted tetrahydroisoquinoline compounds of general formula If and in each case stereoisomers thereof may be obtained in form of a corresponding salt according to methods well known to those skilled in the art, e.g. by reacting said compound with at least one inorganic and/or organic acid, preferably in a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. 
     Compounds of general formula IV are in most cases commercially available or may be prepared by processes known to those skilled in the art. 
     Compounds of general formula V are in most cases commercially available or may be prepared by processes known to those skilled in the art. 
     In particular, 1,2,3,4-tetrahydroisoquinoline compounds with an amino group in position 5 can be prepared starting from 5-nitro-1,2,3,4-tetrahydroisoquinoline compounds. A process for the preparation of the latter compounds is described in K. V. Rao et al., Journal of Heterocyclic Chemistry, 1973, 10, 213 to 215. 
     In particular, 1,2,3,4-tetrahydroisoquinoline compounds with an amino group in position 6 are commercially available or can be prepared starting from 6-nitro-1,2,3,4-tetrahydroisoquinoline compounds. A process for the preparation of the latter compounds is described in G. J. Quallich, Journal of Organic Chemistry, 1998, 63, 4116 to 4119. 
     1,2,3,4-tetrahydroisoquinoline compounds with a nitro group in position 6 or 8 may be prepared by established procedures described in M. Tercel, Journal of Medicinal Chemistry, 1996, 39, 1084 to 1094. 
     In particular, 1,2,3,4-tetrahydroisoquinoline compounds with an amino group in position 7 are commercially available or can be prepared starting from 7-nitro-1,2,3,4-tetrahydroisoquinoline compounds. A process for the preparation of the latter compounds is described in J. F. Ajao et al., Journal of Heterocyclic Chemistry, 1985, 22, 329 to 331. 
     The N-methyl-8-amino-substituted 1,2,3,4-tetrahydroisoquinoline compounds were prepared by bromination and nitration of the corresponding 1,2,3,4-tetrahydroisoquinolines followed by two-step standard reduction conditions as described in M. Rey, Helvetica Chimica Acta, 1985, 66, 1828 to 1834. 
     If any of the substituents in any of the above defined formulae represents or comprises a (hetero)cycloaliphatic radical, preferably a C 3-9  cycloalkyl radical or a C 4-9  cycloalkenyl radical, or a heterocyclic ring, preferably a 3- to 8-membered heterocyclic ring, said (hetero)cycloaliphatic radical, heterocyclic ring, C 3-9  cycloalkyl radical or C 4-9  cycloalkenyl radical may—if not defined otherwise—be unsubstituted or substituted by one or more substituents, preferably unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituent(s) may preferably be selected independently from the group consisting of oxo (═O), thioxo (═S), C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—C 1-5 -alkyl, —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, phenyl, phenoxy and benzyl; whereby in each occurrence C 1-5 -alkyl may be linear or branched and whereby said cyclic substituents may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     More preferably said substituents may be selected independently from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—CH 3 —CH 3 —CH 3 , —C(═O)—O—CH(CH 3 ) 2 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—CH 3 —CH 3 —CH 3 , —C(═O)—CH(CH 3 ) 2 , —C(═O)—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —NH—CH 2 —CH 2 —CH 3 , —NH—CH(CH 3 ) 2 , —NH—C(CH 3 ) 3 , —N(CH 3 ) 2 , —N—(C 2 H 5 ) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O) 2 —CH 3 , —S(═O) 2 -phenyl, phenyl, phenoxy and benzyl; whereby in each occurrence said cyclic substituents may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     If any of the substituents in any of the above defined formulae represents or comprises a cycloaliphatic radical, C 3-9  cycloalkyl radical or C 4-9  cycloalkenyl radical which contains one or more, preferably 1, 2 or 3 heteroatom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) may preferably be selected independently from the group consisting of N, O and S. 
     If any of the substituents in any of the above defined formulae represents or comprises a heterocyclic ring which contains at least one further, preferably 1 or 2 further heteroatom(s) as ring member(s), unless defined otherwise, each of these heteroatom(s) may preferably be selected independently from the group consisting of N, O and S. 
     Suitable saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radicals, C 3-9  cycloalkyl radicals or C 4-9  cycloalkenyl radicals may preferably be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5)-dihydrofuranyl, (2,5)-dihydrothiophenyl, (2,3)-dihydrofuranyl, (2,3)-dihydrofuranyl, (2,5)-dihydro-1H-pyrrolyl, (2,3)-dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4)-dihydro-2H-pyranyl, (3,4)-dihydro-2H-thiopyranyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, [1,3]-oxazinanyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3)-dioxanyl, (1,4)-dioxanyl and (1,3)-dioxolanyl. 
     Suitable saturated or unsaturated heterocyclic rings which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system may preferably be selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, azepanyl, diazepanyl, azocanyl, (1,2,3,6)-tetrahydropyridinyl, (1,2,3,4)-tetrahydropyridinyl, (1,2,5,6)-tetrahydropyridinyl, hexahydropyrimidinyl, (5,6)-dihydro-4H-pyrimidinyl, pyridazin-3(2H)-on-yl, phthalazin-1(2H)-on-yl, indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (1,2,3,4)-tetrahydronaphthyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, octahydropyrrolo[1,2-a]pyrazinyl, octahydro-1H-pyrido[1,2-a]pyrazinyl, dodecahydrocarbazolyl, 9H-carbazolyl, decahydroisoquinolinyl and (2,3)-dihydro-1H-benzo[de]isoquinolinyl. 
     Suitable aromatic heterocyclic rings which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system may preferably be selected from the group consisting of imidazolyl, pyrazolyl, triazolyl, (4,5,6,7)-tetrahydro-2H-indazolyl, indazolyl and benzimidazolyl. 
     Suitable saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radicals, C 3-9  cycloalkyl radicals or C 4-9  cycloalkenyl radicals which are condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system may preferably be selected from the group consisting of indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (1,2,3,4)-tetrahydronaphthyl, octahydro-cyclopenta[c]pyrrolyl, (1,3,4,7,9a)-hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a)-hexahydro-indolizinyl, decahydroquinolinyl, dodecahydrocarbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7)-dihydro-4H-thieno[3,2-c]pyridinyl, (2,3)-dihydro-1H-benzo[de]isoquinolinyl, octahydropyrrolo[1,2-a]pyrazinyl, octahydro-1H-pyrido[1,2-a]pyrazinyl, (1,2,3,7,8,8a)-hexahydroindolizinyl, (2,6,7,8,9,9a)-hexahydro-1H-quinolizinyl, octahydroindolizinyl, octahydro-1H-quinolizinyl, (1,2,3,5,8,8a)-hexahydroindolizinyl, (4,6,7,8,9,9a)-hexahydro-1H-quinolizinyl, fluorenyl and (1,2,3,4)-tetrahydroquinoxalinyl. 
     If any of the substituents in any of the above defined formulae represents an alkylene group, preferably an C 1-6  alkylene group, an alkenylene group, preferably an C 2-6  alkenylene group or an alkinylene group, preferably an C 2-6  alkinylene group, which may be substituted, said alkylene group, C 2-6  alkylene group, alkenylene group, C 2-6  alkenylene group, alkinylene group or C 2-6  alkinylene group may be unsubstituted or substituted by one or more substituents, preferably unsubstituted or optionally substituted with 1, 2 or 3 substituent(s). Said substituent(s) may preferably be selected independently from the group consisting of —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl) and —N(C 1-5 -alkyl) 2 , whereby in each occurrence C 1-5 -alkyl may be linear or branched. An alkenylene group comprises at least one carbon-carbon double bond, an alkinylene group comprises at least one carbon-carbon triple bond. 
     Suitable alkylene groups include —(CH 2 )—, —CH(CH 3 )—, —CH(phenyl), —(CH 2 ) 2 —, —(CH 2 ) 3 —, —(CH 2 ) 4 —, —(CH 2 ) 5  and —(CH 2 ) 6 —, suitable alkenylene groups include —CH═CH—, —CH 2 —CH═CH— and —CH═CH—CH 2 — and suitable alkinylene groups include —C≡C—, —CH 2 —C≡C— and —C≡C—CH 2 —. 
     If any of the substituents in any of the above defined formulae represents or comprises an aryl radical, including a 6-membered aryl radical such as phenyl or a 10-membered aryl radical such as naphthyl or a 14-membered aryl radical such as anthracenyl, said aryl radical may—if not defined otherwise—be unsubstituted or substituted by one or more substituents, preferably unsubstituted or substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituent(s) may preferably be selected independently from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—C 1-5 -alkyl, —O(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —O(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, —C 1-5 -alkylene-C(═O)—OH, —C 1-5 -alkylene—C(═O)—O—C 1-5 -alkyl, —NH—C(═O)—C 1-5 -alkyl, —NH—S(═O) 2 -C 1-5 -alkyl, pyrrolidinyl, piperdinyl, morpholinyl, oxazolyl, isoxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, thiophenyl, furanyl, pyrrolidin-2,5-dionyl, phenyl, phenoxy and benzyl; whereby in each occurrence C 1-5 -alkyl may be linear or branched and whereby said cyclic substituent(s) may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     More preferably said substituents may be selected independently from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—CH 3 —CH 3 —CH 3 , —C(═O)—O—CH(CH 3 ) 2 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—CH 3 —CH 3 —CH 3 , —C(═O)—CH(CH 3 ) 2 , —C(═O)—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —NH—CH 2 —CH 2 —CH 3 , —NH—CH(CH 3 ) 2 , —NH—C(CH 3 ) 3 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2  and —S(═O) 2 —CH 3 . 
     Preferred aryl radicals, which may optionally be at least mono-substituted, are phenyl and naphthyl. 
     Suitable aryl radicals, which are condensed with an unsubstituted or at least mono-substituted saturated or unsaturated mono- or bicyclic ring system, may preferably be selected from the group consisting of indolinyl, isoindolinyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (1,2,3,4)-tetrahydronaphthyl, (1,2,3,4)-tetrahydroquinoxalinyl, benzo[d]oxazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, benzo[d][1,3]dioxolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, isochromanyl, chromanyl, 2,3-dihydrobenzofuranyl and 1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dionyl. 
     If any of the substituents in any of the above defined formulae represents or comprises a heteroaryl radical, including a monocyclic 5- or 6-membered heteroaryl radical or a bi- or tricyclic 8-, 9-, 10-, 11-, 12-, 13- or 14 membered heteroaryl radical, said heteroaryl radical may—if not defined otherwise—be unsubstituted or substituted by one or more substituents, preferably unsubstituted or substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituent(s) may preferably be selected independently from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, —C(═O)—C 1-5 -alkyl, —O(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —CF 3 , —OCF 3 , —SCF 3 , —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —O(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, —C 1-5 -alkylene-C(═O)—OH, —C 1-5 -alkylene-C(═O)—O—C 1-5 -alkyl, —NH—C(═O)—C 1-5 -alkyl, —NH—S(═O) 2 —C 1-5 -alkyl, pyrrolidinyl, piperdinyl, morpholinyl, oxazolyl, isoxazolyl, pyridinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, thiophenyl, furanyl, pyrrolidin-2,5-dionyl, phenyl, phenoxy and benzyl; whereby in each occurrence C 1-5 -alkyl may be linear or branched and whereby said cyclic substituent(s) may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     More preferably said substituents may be selected independently from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—C 2 H 5 , —C(═O)—O—CH 3 —CH 3 —CH 3 , —C(═O)—O—CH(CH 3 ) 2 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—C 2 H 5 , —C(═O)—CH 3 —CH 3 —CH 3 , —C(═O)—CH(CH 3 ) 2 , —C(═O)—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —NH—CH 2 —CH 2 —CH 3 , —NH—CH(CH 3 ) 2 , —NH—C(CH 3 ) 3 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2  and —S(═O) 2 —CH 3 . 
     The heteroatom(s), which are present as ring member(s) in the heteroaryl radical, may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur. Preferably the heteroaryl radical comprises 1, 2, 3 or 4 heteroatom(s). 
     Suitable bi- or tricyclic heteroaryl radicals, which may optionally be at least mono-substituted, may preferably be selected from the group consisting of indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzimidazolyl, benzo[2,1,3]thiadiazolyl, [1,2,3]-benzothiadiazolyl, [2,1,3]-benzoxadiazolyl, [1,2,3]-benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, imidazo[2,1-b]thiazolyl, 2H-chromenyl, indazolyl and quinazolinyl. 
     Suitable mono-, bi- or tricyclic heteroaryl radicals, which are condensed with an unsubstituted or at least mono-substituted saturated or unsaturated mono- or bicyclic ring system, may preferably be selected from the group consisting of [1,3]-benzodioxolyl, [1,4]-benzodioxanyl, [1,2,3,4]-tetrahydronaphthyl, (2,3)-dihydro-1H-cyclopenta[b]indolyl, [1,2,3,4]-tetrahydroquinolinyl, [1,2,3,4]-tetrahydroisoquinolinyl, [1,2,3,4]-tetrahydroquinazolinyl and [3,4]-dihydro-2H-benzo[1,4]oxazinyl. 
     Suitable monocyclic heteroaryl radicals, which may optionally be at least mono-substituted, may preferably be selected from the group consisting of pyridinyl, furyl(furanyl), thiophenyl(thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl and pyranyl. 
     A mono- or bicyclic ring system according to the present invention—if not defined otherwise—means a mono- or bicyclic hydrocarbon ring system that may be saturated, unsaturated or aromatic. Each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or bicyclic ring system may contain one or more, preferably 1, 2 or 3, heteroatom(s) as ring member(s), which may be identical or different and which can preferably be selected from the group consisting of N, O and S. The rings of the mono- or bicyclic ring system are preferably 5-, 6- or 7-membered. 
     Preferably a mono-or bicyclic ring system according to the present invention is a phenyl or naphthyl ring system. 
     The term “condensed” according to the present invention means that a ring or ring system is attached to another ring or ring system, whereby the terms “annulated” or “annelated” are also used by those skilled in the art to designate this kind of attachment. 
     Such a mono- or bicyclic ring system may—if not defined otherwise—be unsubstituted or substituted by one or more substituents, preferably unsubstituted or substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituents may preferably be selected independently from the group consisting of C 1-5 -alkyl, —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, —C(═O)—OH, oxo (═O), thioxo (═S), —C(═O)—O—C 1-5 -alkyl, —O—C(═O)—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl), —N(C 1-5 -alkyl) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH(C 1-5 -alkyl), —C(═O)—N(C 1-5 -alkyl) 2 , —S(═O) 2 —C 1-5 -alkyl, —S(═O) 2 -phenyl, phenyl, phenoxy and benzyl; whereby in each occurrence C 1-5 -alkyl may be linear or branched and whereby said cyclic substituents may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     More preferably said substituents may be selected from the group consisting of oxo (═O), thioxo (═S), methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, n-pentyl, —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—C(CH 3 ) 3 , —C(═O)—OH, —C(═O)—O—CH 3 , —C(═O)—O—O 2 H 5 , —C(═O)—O—CH 3 —CH 3 —CH 3 , —C(═O)—O—CH(CH 3 ) 2 , —C(═O)—O—C(CH 3 ) 3 , —C(═O)—CH 3 , —C(═O)—O 2 H 5 , —C(═O)—CH 3 —CH 3 —CH 3 , —C(═O)—CH(CH 3 ) 2 , —C(═O)—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH—CH 3 , —NH—C 2 H 5 , —NH—CH 2 —CH 2 —CH 3 , —NH—CH(CH 3 ) 2 , —NH—C(CH 3 ) 3 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —NO 2 , —CHO, —CF 2 H, —CFH 2 , —C(═O)—NH 2 , —C(═O)—NH—CH 3 , —C(═O)—NH—C 2 H 5 , —C(═O)—N(CH 3 ) 2 , —C(═O)—N(C 2 H 5 ) 2 , —S(═O) 2 —CH 3 , —S(═O) 2 -phenyl, phenyl, phenoxy and benzyl; whereby in each occurrence said cyclic substituents may be unsubstituted or substituted by 1, 2 or 3 substituent(s) independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, F, Cl, Br, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2  and —NO 2 . 
     If any of the substituents in any of the above defined formulae represents a saturated or unsaturated aliphatic radical, i.e. an alkyl radical, preferably an C 1-10  alkyl radical; an alkenyl radical, preferably an C 2-10  alkenyl radical or an alkinyl radical, preferably an C 2-10  alkinyl radical; said aliphatic radical may—if not defined otherwise—be unsubstituted or substituted by one or more substituents, preferably unsubstituted or substituted with 1, 2, 3, 4 or 5 substituent(s). Said substituent(s) may preferably be selected independently from the group consisting of —O—C 1-5 -alkyl, —S—C 1-5 -alkyl, F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , —NH(C 1-5 -alkyl) and —N(C 1-5 -alkyl) 2 , whereby in each occurrence C 1-5 -alkyl may be linear or branched. More preferably said substituent(s) may preferably be selected independently from the group consisting of —O—CH 3 , —O—C 2 H 5 , —O—CH 2 —CH 2 —CH 3 , —O—CH(CH 3 ) 2 , —O—C(CH 3 ) 3 , —S—CH 3 , —S—C 2 H 5 , —S—CH 2 —CH 2 —CH 3 , —S—CH(CH 3 ) 2 , —S—C(CH 3 ) 3 , F, Cl, Br, I, —CN, —CF 3 , —OCF 3 , —SCF 3 , —OH, —SH, —NH 2 , NH—CH 3 , —NH—C 2 H 5 , —NH—CH 2 —CH 2 —CH 3 , —NH—CH(CH 3 ) 2 , —NH—C(CH 3 ) 3 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 . 
     An alkenyl radical comprises at least one carbon-carbon double bond, an alkinyl radical comprises at least one carbon-carbon triple bond. 
     Suitable alkyl radicals, which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl. 
     Suitable alkenyl radicals, which may be substituted by one or more substituents, may preferably be selected from the group consisting of vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl and 3-butenyl. 
     Suitable alkinyl radicals, which may be substituted by one or more substituents, may preferably be selected from the group consisting of ethinyl, 1-propinyl, 2-propinyl, 1-butinyl, 2-butinyl and 3-butinyl. 
     Also preferably a compound selected from the group consisting of 5-methoxy-tryptamine, bromocriptine, octoclothepin, clozapine, olanzapine, loxapine, chlorpromazine, fluphenazine, BVT-5182, EMDT, Ro 65-7199, Ro 04-6790, Ro 63-0563, MS-245, SB-271046, LY-483518, ALX-0440, WAY-181189, WAY-466, ALX-1175, ALX-1161, SB-271046, SB-258510, SB-357134, SB-214111, SB-399885, Ro 65-7674, SB-699929, Ro 43-68554, SB-742457, Ro 66-0074, [ 11 C]GSK-215083,
         [HT1] N,N-dimethyl-2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine,   [HT2] 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole,   [HT3] 2-(1-(5-(phenylsulfonamido)-1H-indol-3-yl)ethylidene)hydrazinecarboximidamide,   [HT4] 5-fluoro-3-(3-fluorophenylsulfonyl)-1-(piperidin-3-yl)-1H-indole,   [HT5] 2-((1-(4-aminophenylsulfonyl)-1H-indol-3-yl)methylene)hydrazinecarboximidamide,   [HT6] 3-(phenylsulfonyl)-7-(2-(pyrrolidin-1-yl)ethoxy)-1H-indole,   [HT7] N,N-dimethyl-2-(1-(phenylsulfonyl)-1H-indol-4-yloxy)ethanamine,   [HT8] 1-(phenylsulfonyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole,   [HT9] 2-(3-benzyl-1H-indol-1-yl)-N,N-dimethylethanamine,   [HT10] 4-(3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-1-ylsulfonyl)benzenamine,   [HT12] (6S,7S)-7-(dimethylamino)-2-tosyl-2,6,7,8-tetrahydrobenzo[cd]indol-6-ol,   [HT13] 2-(1-(phenylsulfonyl)-6,7-dihydro-1H-indol-4(5H)-ylidene)hydrazinecarboximidamide,   [HT14] 6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine,   [HT15] 3-(3-chlorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine,   [HT16] 4-(5,6,7,8-tetrahydrocarbazol-9-ylsulfonyl)benzenamine,   [HT17] 3-(2-aminoethyl)-1-(naphthalen-2-ylsulfonyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one,   [HT18] 2-(4-(6-chloroimidazo[2,1-b]thiazol-5-ylsulfonyl)-4H-thieno[3,2-b]pyrrol-6-yl)-N,N-dimethylethanamine,   [HT19] N,N-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine,   [HT20] N-(4-(piperidin-4-yl)-2H-chromen-6-yl)naphthalene-1-sulfonamide,   [HT21] 2-(3-benzyl-3H-inden-1-yl)-N,N-dimethylethanamine,   [HT22] N-(7-((3S,4S)-3-fluoropiperidin-4-yloxy)benzofuran-5-yl)-2-methoxy-5-methylbenzenesulfonamide,   [HT23] 2-Methoxy-10-(1-methylpyrrolidin-3-yl)-5-thia-4b-aza-indeno[2,1-a]indene 5,5-dioxide,   [HT24] 1-(6-(phenylsulfonyl)pyridin-3-yl)piperazine,   [HT25] 1-(2-methoxy-5-(naphthalen-1-ylsulfonyl)phenyl)piperazine,   [HT26] 1-(2-chloro-5-(phenylsulfonyl)phenyl)piperazine,   [HT27] 8-methoxy-1-(3-methoxy-5-(piperazin-1-yl)benzyl)-3,4-dihydroquinolin-2(1H)-one,   [HT28] 5-chloro-3-(3-chlorophenylsulfonyl)-7-(4-methylpiperazin-1-yl)-1H-indole,   [HT29] 1-(4-(phenylsulfonyl)naphthalen-1-yl)piperazine,   [HT30] 3-(phenylsulfonyl)-7-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridine,   [HT31] 4-(2-chlorophenylsulfonyl)-6-methyl-8-(piperazin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine,   [HT32] 5-(4-methylpiperazin-1-yl)-3-(naphthalen-1-ylsulfonyl)-1H-indazole,   [HT33] 4-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)piperazin-1-yl)-1H-indol-1-ylsulfonyl)benzenamine,   [HT34] 5-(4-benzylpiperazin-1-yl)-3-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine,   [HT35] 2-(2,3-dichlorophenylsulfonyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline,   [HT36] 6-fluoro-4-(2-fluorobenzyl)-8-(piperazin-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one,   [HT37] 2-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole,   [HT38] 4-(4-(piperazin-1-yl)naphthalen-1-ylsulfonyl)benzenamine,   [HT39] 8-(4-(4-fluorobenzyl)piperazin-1-yl)-3-(phenylsulfonyl)quinoline,   [HT40] 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)benzenesulfonamide,   [HT41] 2-(methylthio)-3-(phenylsulfonyl)-4H-pyrido[1,2-a]pyrimidin-4-imine and   [HT42] 8-(4-(3-fluoro-5-(trifluoromethyl)benzyl)phenylsulfonyl)-N,N,3-trimethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-amine;
 
or salts, free bases, racemates or enantiomers thereof, is present as component (A).
       

     The structure of these compounds is depicted below: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     The compounds ALX-0440, ALX-1161 and ALX-1175 can prepared according to the disclosure of WO 2000/63203. 
     The compounds MS-245, HT12 and HT1 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2000, 10, 2295-2299 and J. Med. Chem. 2001, 44, 3881-3895. 
     The compound Ro 65-1799 can be prepared according to the disclosure of Eur. J. Med. Chem. 2001, 36, 165-178. 
     The compound HT2 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 4230-4234. 
     The compound LY-483518 or SGS518 can be prepared according to the disclosure of WO 2002/60871. 
     The compound WAY-181187 can be prepared according to the disclosure of WO 2003/53433 and WO 2006/2125. 
     The compound HT3 can be prepared according to the disclosure of US 2003/232843. 
     The compound HT4 can be prepared according to the disclosure of WO 2004/9548. 
     The compound HT5 can be prepared according to the disclosure of US 2004/2527. 
     The compound HT6 can be prepared according to the disclosure of WO 2004/50085. 
     The compound WAY-466 can be prepared according to the disclosure of J. Med. Chem. 2005, 48, 353-356. 
     The compound HT7 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 1393-1396. 
     The compound HT8 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 3510-3513. 
     The compounds HT9 and HT21 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 1987-1991. 
     The compound HT10 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 379-383. 
     The compound HT11 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 4780-4785. 
     The compound HT13 can be prepared according to the disclosure of WO 2003/68740. 
     The compound HT14 can be prepared according to the disclosure of WO 2003/30901. 
     The compound HT15 can be prepared according to the disclosure of WO 2004/9600. 
     The compound HT16 can be prepared according to the disclosure of Biorg. Med. Chem. Lett. 2004, 14, 1961-1964. 
     The compound HT17 can be prepared according to the disclosure of WO 2005/10003. 
     The compound HT18 can be prepared according to the disclosure of WO 2005/12311. 
     The compound HT19 can be prepared according to the disclosure of US 2005/101596. 
     The compound HT20 can be prepared according to the disclosure of WO 2005/37830. 
     The compound HT22 can be prepared according to the disclosure of WO 2005/58858. 
     The compound HT23 can be prepared according to the disclosure of WO 2005/66184. 
     The compounds SB-271040 and SB-258510 can be prepared according to the disclosure of J. Med. Chem. 1999, 42, 202-205. 
     The compound SB-357134 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2001, 11, 55-58. 
     The compound HT24 can be prepared according to the disclosure of WO 2003/72548. 
     The compound HT25 can be prepared according to the disclosure of WO 2003/14097. 
     The compound HT26 can be prepared according to the disclosure of WO 2004/80968. 
     The compound HT27 can be prepared according to the disclosure of WO 2004/80969. 
     The compounds SB-699929 and HT28 can be prepared according to the disclosure of WO 2002/41889. 
     The compound Ro 43-68554 can be prepared according to the disclosure of WO 2002/98857. 
     The compound HT29 can be prepared according to the disclosure of WO 2003/72558. 
     The compound HT30 can be prepared according to the disclosure of WO 2003/80608. 
     The compound BVT-5182 can be prepared according to the disclosure of WO 2002/102774. 
     The compound HT31 can be prepared according to the disclosure of WO 2003/95434. 
     The compound SB-742457 can be prepared according to the disclosure of WO 2003/80580. 
     The compound HT32 can be prepared according to the disclosure of US 2004/167122. 
     The compound HT33 can be prepared according to the disclosure of US 2004/192749. 
     The compound HT34 can be prepared according to the disclosure of WO 2004/74286. 
     The compound HT35 can be prepared according to the disclosure of WO 2004/78176. 
     The compound HT36 can be prepared according to the disclosure of US 2004/92512. 
     The compound HT37 can be prepared according to the disclosure of WO 2004/26831. 
     The compound HT38 can be prepared according to the disclosure of Bioorg. Med. Chem. Lett. 2005, 15, 1707-1711. 
     The compound HT39 can be prepared according to the disclosure of WO 2005/26125. 
     The compounds Ro 04-6790 and Ro 63-0563 can be prepared according to the disclosure of Br. J. Phamacol. 1998, 124, 556-562. 
     The compound HT40 can be prepared according to the disclosure of WO 2003/68751. 
     The compound Ro 66-0074 can be prepared according to the disclosure of J. Med. Chem. 2003, 46, 1273-1276. 
     The compound HT41 can be prepared according to the disclosure of US 2004/19064. 
     The compound HT42 can be prepared according to the disclosure of WO 2005/51398. 
     The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Those skilled in the art understand that according to the present invention any combination of compounds with 5-HT 6  receptor affinity may be present as component (A) in the active substance combination. Also any combination of cholinesterase inhibitors may be present as component (B) in the active substance combination. 
     Particularly preferably a compound selected from the group consisting of 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide, 1-[1-(Naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 5-chloro-3-methyl-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, BVT-5182, EMDT, Ro 04-6790, Ro 63-0563, MS-245, SB-271046, ALX-1175 and ALX-1161, or salts, free bases, racemates or enantiomers thereof, is present as component (A). 
     More particularly preferably the compound [1140] 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide (also known as E-6801) and/or 5-chloro-3-methyl-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide [1141] and/or 1-[1-(Naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one [1b] as depicted below is present as component (A). 
     
       
         
         
             
             
         
       
     
     Examples of preferred acetylcholinesterase inhibitors according to the present invention include edrophonium, ganstigmine, demecarium, ambenonium, neostigmine bromide, dehydroevodiamine chloride, eseroline, imperatorin, scopoletin (SCT), huperizine A (Hup A), huperzine A, tacrine hydrochloride (CI-970, THA.HCl), 7-methoxytacrine (7-MEOTA), velnacrine maleate (HP-029, P83-6029A), rivastigmine tartrate (ENA-713, ENA-713D, ONO-2540, SDZ-212-713, SDZ-ENA-713), eptastigmine tartrate (L-693487), heptylstigmine tartrate (MF-201), donepezil hydrochloride (BNAG, E-2020), suronacrine maleate (HP-128), UCB-11056, SM-10888, stacofylline hydrochloride (S-9977, S-9977-2), berberine iodide, zifrosilone (MDL-73745), norpyridostigmine, quilostigmine (HP-290, NXX-066), E-2030, THB-013, F-3796, PD-142012, CI-1002, PD-142676, terestigmine tartrate (CHF-2060), thiacymserine, phenserine tartrate, galantamine hydrobromide (GP-37267), galantamine hydrobromide (R-113675), Ro-46-5934, P11012, MF-8615, MF-268 bitartrate, anseculin hydrochloride (KA-672.HCl), ensaculin hydrochloride, icopezil maleate (CP-118954, CP-118954-11), eserine salicylate, physostigmine salicylate, isovanihuperzine A (IVHA), JWS-USC-75IX, FR-152558, UR-1827, P11467, P-10358, bis(7)-tacrine, HMR-2420, T-82, CP-126998, TV-3279, MSF, THA-C8, subergorgic acid, suberogorgin, SPH-1286, huperzine B (Hup B), pyridostigmine bromide (Ro-1-5130), huprine X, ER-127528, tolserine tartrate, huprine Y, coronaridine, RS-1233, kobophenol A, bis(12)-huperine, BGC-20-1259, RS-1259, NP-7557, ZT-1, ITH-4012, TK-19, T-81, TH-171, TH-185, distigmine bromide (BC-51), (−)-9-dehydrogalanthaminium bromide, memoquin, NP-0361, scopoletin 7-O-beta-D-glucopyranoside (NSC-404560), scopolin (SCN), scopoloside, BW-284c51, SP-004, SP-04, withaferin A (NSC-101088), withaferine (NSC-273757), (+)-corynoline, corynoline, (S)-(−)-oxypeucedanin, oxypeucedanin, (−)-voacangine, carbomethoxyibogaine, voacangine, dieckol, phlorofucofuroeckol (PFF), phlorofucofuroeckol A, (−)-3-O-acetylspectaline hydrochloride and rhaphiasaponin 1, or salts, free bases, racemates or enantiomers thereof. 
     Exemplary reversible inhibitors include tacrine, donepezil, edrophonium and galantamine. Exemplary pseudo-irreversible inhibitors include physostigmine, eptastigmine, pyridostigmine, neostigmine, ganstigmine and rivastigmine. Pseudo-irreversible cholinesterase inhibitors also include carbamate insecticides, including carbaryl (Sevin), propoxur (Baygon), and aldicarb (Temik). Typically, pseudo-irreversible acetylcholinesterase inhibitors comprise a carbamate moiety, for example, rivastigmine, eptastigmine, physostigmine, neostigmine, demecarium, ambenonium, pyridostigmine, and ganstigmine. Additional cholinesterase inhibitors that can find use in the present invention include huperzine A, T-82, phenserine, quilostigmine, and TAK-147. 
     Huperzine A, a novel potent, reversible, and selective acetylcholinesterase (AchE) inhibitor has been expected to be superior to other AchE inhibitors now known for the treatment of memory deficits in patients with Alzheimer&#39;s disease. It has been shown to inhibit the enzyme that is responsible for the breakdown of acetylcholine, an important neurotransmitter, or brain chemical, which is critical in not only memory and/or learning but is critical in peripheral nervous system as well. This could have a beneficial effect in the disorder known as Myastenia Gravis. Huperzine is a naturally occurring compound that was originally isolated from the club moss Huperzine Serrata. It has been used in Chinese folk medicine and more recently in limited clinical trials conducted in China as a treatment for age-related memory disorders. 
     More preferably a cholinesteresterase inhibitor selected from the group consisting of huperzine A, rivastigmine, pyridostigmine, distigmine, neostigmine, physostigmine, tacrine, galantamine and donepezil is present as component (B). 
     Even more preferably donepezil is present as component (B). 
     Preferably the acetylcholinesterase inhibitor of the present also includes one or more of a cholinesterase inhibitory agent that binds to the acyl pocket of the active centre of AChE, the choline subsite of the active center of AChE, or the peripheral anionic site of AChE. For example, edrophonium and tacrine bind to the choline subsite in the vicinity of tryptophan 86 and glutamate 202 of AChE. Donepezil binds with higher affinity to the active center of AChE. Propidium and the peptide toxin fasciculin bind to the peripheral anionic site on AChE. This is reviewed in Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, supra, at pages 175-89. 
     Preferred is an active substance combination that comprises at least one compound selected from the group consisting of 6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide, 1-[1-(Naphthalene-1 -sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 5-chloro-3-methyl-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide, 5-methoxy-tryptamine, bromocriptine, octoclothepin, clozapine, olanzapine, loxapine, chlorpromazine, fluphenazine, BVT-5182, EMDT, Ro 65-7199, Ro 04-6790, Ro 63-0563, MS-245, SB-271046, LY-483518, ALX-0440, WAY-181189, WAY-466, ALX-1175, ALX-1161, SB-271046, SB-258510, SB-357134, SB-214111, SB-399885, Ro 65-7674, SB-699929, Ro 43-68554, SB-742457, Ro 66-0074, [ 11 C]GSK-215083,
         [HT1] N,N-dimethyl-2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine,   [HT2] 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole,   [HT3] 2-(1-(5-(phenylsulfonamido)-1H-indol-3-yl)ethylidene)hydrazinecarboximidamide,   [HT4] 5-fluoro-3-(3-fluorophenylsulfonyl)-1-(piperidin-3-yl)-1H-indole,   [HT5] 2-((1-(4-aminophenylsulfonyl)-1H-indol-3-yl)methylene)hydrazinecarboximidamide,   [HT6] 3-(phenylsulfonyl)-7-(2-(pyrrolidin-1-yl)ethoxy)-1H-indole,   [HT7] N,N-dimethyl-2-(1-(phenylsulfonyl)-1H-indol-4-yloxy)ethanamin,   [HT8] 1-(phenylsulfonyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole,   [HT9] 2-(3-benzyl-1H-indol-1-yl)-N,N-dimethylethanamine,   [HT10] 4-(3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-1-ylsulfonyl)benzenamine,   [HT12] (6S,7S)-7-(dimethylamino)-2-tosyl-2,6,7,8-tetrahydrobenzo[cd]indol-6-ol,   [HT13] 2-(1-(phenylsulfonyl)-6,7-dihydro-1H-indol-4(5H)-ylidene)hydrazinecarboximidamide,   [HT14] 6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine,   [HT15] 3-(3-chlorophenylsulfonyl)-1-(pyrrolidin-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine,   [HT16] 4-(5,6,7,8-tetrahydrocarbazol-9-ylsulfonyl)benzenamine,   [HT17] 3-(2-aminoethyl)-1-(naphthalen-2-ylsulfonyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one,   [HT18] 2-(4-(6-chloroimidazo[2,1-b]thiazol-5-ylsulfonyl)-4H-thieno[3,2-b]pyrrol-6-yl)-N,N-dimethylethanamine,   [HT19] N,N-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine,   [HT20] N-(4-(piperidin-4-yl)-2H-chromen-6-yl)naphthalene-1-sulfonamide,   [HT21] 2-(3-benzyl-3H-inden-1-yl)-N,N-dimethylethanamine,   [HT22] N-(7-((3S,4S)-3-fluoropiperidin-4-yloxy)benzofuran-5-yl)-2-methoxy-5-methylbenzenesulfonamide,   [HT23] 2-Methoxy-10-(1-methylpyrrolidin-3-yl)-5-thia-4b-aza-indeno[2,1-a]indene 5,5-dioxide,   [HT24] 1-(6-(phenylsulfonyl)pyridin-3-yl)piperazine,   [HT25] 1-(2-methoxy-5-(naphthalen-1-ylsulfonyl)phenyl)piperazine,   [HT26] 1-(2-chloro-5-(phenylsulfonyl)phenyl)piperazine,   [HT27] 8-methoxy-1-(3-methoxy-5-(piperazin-1-yl)benzyl)-3,4-dihydroquinolin-2(1H)-one,   [HT28] 5-chloro-3-(3-chlorophenylsulfonyl)-7-(4-methylpiperazin-1-yl)-1H-indole,   [HT29] 1-(4-(phenylsulfonyl)naphthalen-1-yl)piperazine,   [HT30] 3-(phenylsulfonyl)-7-(piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridine,   [HT31] 4-(2-chlorophenylsulfonyl)-6-methyl-8-(piperazin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine,   [HT32] 5-(4-methylpiperazin-1-yl)-3-(naphthalen-1-ylsulfonyl)-1H-indazole,   [HT33] 4-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)piperazin-1-yl)-1H-indol-1-ylsulfonyl)benzenamine,   [HT34] 5-(4-benzylpiperazin-1-yl)-3-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine,   [HT35] 2-(2,3-dichlorophenylsulfonyl)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline,   [HT36] 6-fluoro-4-(2-fluorobenzyl)-8-(piperazin-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one,   [HT37] 2-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole,   [HT38] 4-(4-(piperazin-1-yl)naphthalen-1-ylsulfonyl)benzenamine,   [HT39] 8-(4-(4-fluorobenzyl)piperazin-1-yl)-3-(phenylsulfonyl)quinoline,   [HT40] 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)benzenesulfonamide,   [HT41] 2-(methylthio)-3-(phenylsulfonyl)-4H-pyrido[1,2-a]pyrimidin-4-imine and   [HT42] 8-(4-(3-fluoro-5-(trifluoromethyl)benzyl)phenylsulfonyl)-N,N,3-trimethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-amine;
 
or salts, free bases, racemates or enantiomers thereof,
       

     as component (A); 
     and at least one compound selected from the group consisting of edrophonium, ganstigmine, demecarium, ambenonium, neostigmine bromide, dehydroevodiamine chloride, eseroline, imperatorin, scopoletin (SCT), huperizine A (Hup A), huperzine A, tacrine hydrochloride (CI-970, THA.HCl), 7-methoxytacrine (7-MEOTA), velnacrine maleate (HP-029, P83-6029A), rivastigmine tartrate (ENA-713, ENA-713D, ONO-2540, SDZ-212-713, SDZ-ENA-713), eptastigmine tartrate (L-693487), heptylstigmine tartrate (MF-201), donepezil hydrochloride (BNAG, E-2020), suronacrine maleate (HP-128), UCB-11056, SM-10888, stacofylline hydrochloride (S-9977, S-9977-2), berberine iodide, zifrosilone (MDL-73745), norpyridostigmine, quilostigmine (HP-290, NXX-066), E-2030, THB-013, F-3796, PD-142012, CI-1002, PD-142676, terestigmine tartrate (CHF-2060), thiacymserine, phenserine tartrate, galantamine hydrobromide (GP-37267), galantamine hydrobromide (R-113675), Ro-46-5934, P11012, MF-8615, MF-268 bitartrate, anseculin hydrochloride (KA-672.HCl), ensaculin hydrochloride, icopezil maleate (CP-118954, CP-118954-11), eserine salicylate, physostigmine salicylate, isovanihuperzine A (IVHA), JWS-USC-751X, FR-152558, UR-1827, P11467, P-10358, bis(7)-tacrine, HMR-2420, T-82, CP-126998, TV-3279, MSF, THA-C8, subergorgic acid, suberogorgin, SPH-1286, huperzine B (Hup B), pyridostigmine bromide (Ro-1-5130), huprine X, ER-127528, tolserine tartrate, huprine Y, coronaridine, RS-1233, kobophenol A, bis(12)-huperine, BGC-20-1259, RS-1259, NP-7557, ZT-1, ITH-4012, TK-19, T-81, TH-171, TH-185, distigmine bromide (BC-51), (−)-9-dehydrogalanthaminium bromide, memoquin, NP-0361, scopoletin 7-O-beta-D-glucopyranoside (NSC-404560), scopolin (SCN), scopoloside, BW-284c51, SP-004, SP-04, withaferin A (NSC-101088), withaferine (NSC-273757), (+)-corynoline, corynoline, (S)-(−)-oxypeucedanin, oxypeucedanin, (−)-voacangine, carbomethoxyibogaine, voacangine, dieckol, phlorofucofuroeckol (PFF), phlorofucofuroeckol A, (−)-3-O-acetylspectaline hydrochloride and rhaphiasaponin 1, or salts, free bases, racemates or enantiomers thereof, 
     as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and donepezil as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and huperzine A as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and rivastigmine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and galantamine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and tacrine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and physostigmine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and pyridostigmine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and distigmine as component (B). 
     Particularly preferred is an active substance combination that comprises 1140 as component (A) and neostigmine as component (B). 
     “Obesity” is a condition in which there is an excess of body fat. The operational definition of obesity is based on the Body Mass Index(BMI), which is calculated as body weight per height in meters squared (kg/m 2 ).“Obesity” refers to a condition whereby an otherwise healthy subject has a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 , or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m 2 . An “obese subject” is an otherwise healthy subject with a Body Mass Index (BMI) greater than or equal to 30 kg/m 2  or a subject with at least one co-morbidity with a BMI greater than or equal to 27 kg/m 2 . A “subject at risk of obesity” is an otherwise healthy subject with a BMI of 25 kg/m 2  to less than 30 kg/m 2  or a subject with at least one co-morbidity with a BMI of 25 kg/m 2  to less than 27 kg/m 2 . 
     The increased risks associated with obesity occur at a lower Body Mass Index(BMI) in Asians. In Asian countries, including Japan, “obesity” refers to a condition whereby a subject with at least one obesity-induced or obesity-related co-morbidity, that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m 2 . In Asian countries, including Japan, an “obese subject” refers to a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m 2 . In Asia-Pacific, a “subject at risk of obesity” is a subject with a BMI of greater than 23 kg/m 2  to less than 25 kg/m 2 . 
     As used herein, the term “obesity” is meant to encompass all of the above definitions of obesity. 
     Obesity-induced or obesity-related co-morbidities include, but are not limited to, diabetes, non-insulin dependent diabetes mellitus-type II (2), impaired glucose tolerance, impaired fasting glucose, insulin resistance syndrome, dyslipidemia, hypertension, hyperuricacidemia, gout, coronary artery disease, myocardial infarction, angina pectoris, sleep apnea syndrome, Pickwickian syndrome, fatty liver; cerebral infarction, cerebral thrombosis, transient ischemic attack, orthopedic disorders, arthritis deformans, lumbodynia, emmeniopathy, and infertility. 
     In particular, co-morbidities include: hypertension, hyperlipidemia, dyslipidemia, glucose intolerance, cardiovascular disease, sleep apnea, diabetes mellitus, and other obesity-related conditions. 
     The term “cognitive disorder” indicates disruptions in performance including one or more of the following signs: 
     1) memory deficits (impaired ability to learn new information or recall previously learned information; 
     2) one (or more) of the following disturbances: 
     a) aphasia (language disturbance) 
     b) apraxia (impaired ability to carry out motor activities despite intact motor function) 
     c) agnosia (failure to recognize or identify objects despite in tact sensory function) 
     d) disturbance in executive functioning (i.e. planning, organizing, sequencing, abstracting); 
     3) memory disturbances causing significant impairment in social or occupational functioning, and representing a significant decline from a previous level of functioning; and 
     4) impairment in cognitive functioning as evidenced by neuropsychological testing or quantified clinical assessment, accompanied by objective evidence of a systemic general medical condition or central nervous system dysfunction. 
     Cognitive disorders may include Alzheimer&#39;s disease, learning disabilities caused by degenerative disorders, learning disabilities caused by non-degenerative disorders, memory or cognitive dysfunction such as mild cognitive impairment, age-related cognitive decline, cerebral senility, vascular dementia, AIDS-associated dementia, electric shock induced amnesia, memory impairment associated with depression or anxiety, cognitive defects in Parkinson&#39;s disease, Down&#39;s syndrome, stroke, traumatic brain injury, Huntington&#39;s disease, and attention deficit disorder. 
     “Treatment” (of obesity and obesity-related disorders) refers to the administration of the compounds or combinations of the present invention to reduce or maintain the body weight of an obese subject. One outcome of treatment may be reducing the body weight of an obese subject relative to that subject&#39;s body weight immediately before the administration of the compounds or combinations of the present invention. Another outcome of treatment may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy. 
     Another outcome of treatment may be decreasing the occurrence of and/or the severity of obesity-related diseases. Another outcome of treatment may be to maintain weight loss. The treatment may suitably result in a reduction in food or calorie intake by the subject, including a reduction in total food intake, or a reduction of intake of specific components of the diet such as carbohydrates or fats; and/or the inhibition of nutrient absorption; and/or the inhibition of the reduction of metabolic rate; and in weight reduction in patients in need thereof. The treatment may also result in an alteration of metabolic rate, such as an increase in metabolic rate, rather than or in addition to an inhibition of the reduction of metabolic rate; and/or in minimization of the metabolic resistance that normally results from weight loss. 
     The term “Metabolic syndrome”, also known as syndrome X, is defined in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-E). E. S. Ford et al., JAMA, Vol. 287 (3), Jan. 16, 2002, pp 356-359. Briefly, a person is defined as having Metabolic syndrome if the person has three or more of the following symptoms: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting plasma glucose. 
     The terms “administration of and or “administering a” compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to a subject in need of treatment. 
     The instant pharmaceutical composition includes administration of a single pharmaceutical dosage formulation which contains both the compound with 5-HT 6  receptor affinity, and at least one cholinesterase inhibitor, as well as administration of each active agent in its own separate pharmaceutical dosage formulation. Where separate dosage formulations are used, the individual components of the composition can be administered at essentially the same time, i. e., concurrently, or at separately staggered times, i. e. sequentially prior to or subsequent to the administration of the other component of the composition. The instant pharmaceutical composition is therefore to be understood to include all such regimes of simultaneous or alternating treatment, and the terms “administration” and “administering” are to be interpreted accordingly. 
     Administration in these various ways are suitable for the present compositions as long as the beneficial pharmaceutical effect of the combination of the compound with 5-HT 6  receptor affinity, and at least one cholinesterase inhibitor, is realised by the patient at substantially the same time. 
     Such beneficial effect is preferably achieved when the target blood level concentrations of each active drug are maintained at substantially the same time. It is preferred that the combination of the compound with 5-HT 6  receptor affinity, and at least one cholinesterase inhibitor, be co-administered concurrently on a once-a-day dosing schedule; however, varying dosing schedules, such as the compound with 5-HT 6  receptor affinity once a day and the cholinesterase inhibitor once, twice or more times per day, is also encompassed herein. A single oral dosage formulation comprised of both a compound with 5-HT 6  receptor affinity and a cholinesterase inhibitor is preferred. A single dosage formulation will provide convenience for the patient, which is an important consideration especially for patients with diabetes or obese patients who may be in need of multiple medications. 
     The term “subject” as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. 
     The administration of the composition of the present invention in order to practice the present methods of therapy is carried out by administering a therapeutically effective amount of the compounds in the composition to a subject in need of such treatment or prophylaxis. The need for a prophylactic administration according to the methods of the present invention is determined via the use of well known risk factors. The effective amount of an individual compound is determined, in the final analysis, by the physician in charge of the case, but depends on factors such as the exact disease to be treated, the severity of the disease and other diseases or conditions from which the patient suffers, the chosen route of administration, other drugs and treatments which the patient may concomitantly require, and other factors in the physician&#39;s judgement. 
     The term “therapeutically effective amount” as used herein means the amount of the active compounds in the composition that will elicit the biological or medical response in a tissue, system, subject, or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disorder being treated. The novel methods of treatment of this invention are for disorders known to those skilled in the art. 
     The term “salt” as used herein is to be understood as meaning any form of the compounds in which they assume an ionic form or are charged and are coupled with a counter-ion (a cation or anion) or are in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes which are complexed via ionic interactions. 
     The term “physiologically acceptable salt” is understood in particular, in the context of this invention, as salt (as defined above) formed either with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated—especially if used on humans and/or mammals—or with at least one, preferably inorganic, cation which are physiologically tolerated—especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, hydrobromide, monohydrobromide, monohydrochloride or hydrochloride, salicylic acid, methiodide, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, hippuric acid, picric acid and/or aspartic acid. Examples of physiologically tolerated salts of particular bases are salts of alkali metals and alkaline earth metals and with NH 4 . 
     Solvates, preferably hydrates, of the compounds of the present invention and in each case of corresponding stereoisomers may also be obtained by standard procedures known to those skilled in the art. 
     The term “solvate” according to this invention is to be understood as meaning any form of the compounds in which they have attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate. 
     The active substance combination according to this invention comprises preferably 1-99% by weight of component (A) and 99-1% by weight of component (B), more preferably 70 to 95% by weight of component (A) and 30 to 5% by weight of component (B), even more preferably 85 to 95% by weight of component (A) and 15 to 5% by weight of component (B), in each case referring to the total weight of both components (A) and (B). 
     Another aspect of the present invention is the active substance combination of the invention for its use as a medicament. 
     Another aspect of the present invention is the use of an inventive active substance combination as defined above for the manufacture of a medicament for simultaneous acetylcholinesterase inhibition and 5-HT 6 -receptor regulation. 
     Another aspect of the present invention is the use of the inventive active substance combination for the manufacture of a medicament for the regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin-dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome, for prophylaxis and/or treatment of Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, preferably bipolar disorders, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, neurodegenerative disorders, preferably Alzheimer&#39;s disease, Parkinson&#39;s diesease, Huntington&#39;s Disease and/or multiple sclerosis, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatoric diseases, immunologic diseases or for improvement of cognition. 
     Particularly preferred is the use of the inventive active substance combination for the manufacture of a medicament for the regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin-dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome. 
     Also particularly preferred is the use of the inventive active substance combination for the manufacture of a medicament for prophylaxis and/or treatment of cognitive disorders, memory disorders, or senile dementia processes, such as Alzheimer&#39;s, Parkinson&#39;s and/or Huntington&#39;s Disease. 
     More particularly preferred is the use of the inventive active substance combination for the manufacture of a medicament for prophylaxis and/or treatment of obesity, cognitive disorders, memory disorders, or senile dementia processes, such as Alzheimer&#39;s, Parkinson&#39;s and/or Huntington&#39;s Disease. 
     Also particularly preferred is the use of the active substance combination for the manufacture of a medicament for the prophylaxis and/or treatment of obesity-related disorders such as elevated plasma insulin concentrations and insulin resistance, dyslipidemias, hyperlipidemia, endometrial, breast, prostate and colon cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythms and arrythmias, myocardial infarction, congestive heart failure, coronary heart disease, sudden death, stroke, polycystic ovary disease, craniopharyngioma, the Prader-Willi Syndrome and Frohlich&#39;s syndrome. Further examples of obesity-related disorders are reproductive hormone abnormalities, sexual and reproductive dysfunction, such as impaired fertility, infertility, hypogonadism in males and hirsutism in females, fetal defects associated with maternal obesity, gastrointestinal motility disorders, such as obesity-related gastro-esophageal reflux, respiratory disorders, such as obesity-related hypoventilation syndrome (Pickwickian syndrome), breathlessness, cardiovascular disorders, inflammation, such as systemic inflammation of the vasculature, arteriosclerosis, hypercholesterolemia, hyperuricaemia, lower back pain, gallbladder disease, gout, kidney cancer, and increased anesthetic risk. 
     Those skilled in the art understand that the components (A) and (B) of the active substance combination according to the present invention may be administered simultaneously or sequentially to one another, whereby in each case components (A) and (B) may be administered via the same or different administration pathways, e.g. orally or parentally. preferably both components (A) and (B) are administered simultaneously in one and the same administration form. 
     Yet another aspect of the present invention are pharmaceutical formulations in different pharmaceutical forms comprising an inventive active substance combination and optionally one or more pharmacologically acceptable adjuvants. 
     As well known to somebody skilled in the art the pharmaceutical formulations may—depending on their route of administration, also contain one or more auxiliary substances known to those skilled in the art. 
     The pharmaceutical formulations according to the present invention may be produced according to standard procedures known to those skilled in the art, e.g. from the tables of contents from “Pharmaceutics: the Science of Dosage Forms”, Second Edition, Aulton, M. E. (Ed.) Churchill Livingstone, Edinburgh (2002); “Encyclopedia of Pharmaceutical Technology”, Second Edition, Swarbrick, J. and Boylan J. C. (Eds.), Marcel Dekker, Inc. New York (2002); “Modern Pharmaceutics”, Fourth Edition, Banker G. S. and Rhodes C. T. (Eds.) Marcel Dekker, Inc. New York 2002 and “The Theory and Practice of Industrial Pharmacy”, Lachman L., Lieberman H. and Kanig J. (Eds.), Lea &amp; Febiger, Philadelphia (1986). The respective descriptions are incorporated by reference and are part of the disclosure. 
     Preferred pharmaceutical formulations are solid pharmaceutical forms, preferably tablets, chewing tablets, chewing gums, dragees, capsules, suppositories, powder preparations, transdermal therapeutic systems, transmucosal therapeutic systems, preferably tablets or capsules. 
     Preferred pharmaceutical formulations are also liquid and semi-liquid pharmaceutical forms such as drops or such as juice, sirup, solution, emulsion, suspension, preferably drops or solutions. 
     In an additional preferred embodiment, the pharmaceutical formulations are in the form of multiparticulates, preferably microtablets, microcapsules, microspheroids, granules, crystals or pellets, optionally compacted in a tablet, filled in a capsule or suspended in a suitable liquid. 
     The pharmaceutical formulations according to the present invention are particularly preferably suitable for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application, more particularly for oral, intravenous or intraperitoneal application. 
     In one embodiment of the present invention the pharmaceutical formulation comprises at least one of the components (A) and (B) of the active substance combination at least partially in a sustained-release form. 
     By incorporating one or both of these components (A) and (B) at least partially or completely in a sustained-release form it is possible to extend the duration of their effect, allowing for the beneficial effects of such a sustained-release form, e.g. the maintenance of even concentrations in the blood. 
     Suitable sustained-release forms as well as materials and methods for their preparation are known to those skilled in the art, e.g. from the tables of contents from “Modified-Release Drug Delivery Technology”, Rathbone, M. J. Hadgraft, J. and Roberts, M. S. (Eds.), Marcel Dekker, Inc., New York (2002); “Handbook of Pharmaceutical Controlled Release Technology”, Wise, D. L. (Ed.), Marcel Dekker, Inc. New York, (2000); “Controlled Drug Delivery”, Vol. I, Basic Concepts, Bruck, S. D. (Ed.), CRC Press Inc., Boca Raton (1983) and from Takada, K. and Yoshikawa, H., “Oral Drug delivery”, Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley &amp; Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., “Oral drug delivery, small intestine and colon”, Encylopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley &amp; Sons, Inc., New York (1999), Vol. 2, 698-728. The respective descriptions are incorporated by reference and are part of the disclosure. 
     If the pharmaceutical formulation according to the present invention comprises at least one of the components (A) and (B) at least partially in a sustained-release form, said sustained release may preferably be achieved by the application of at least one coating or provision of a matrix comprising at least one sustained-release material. 
     The sustained-release material is preferably based on an optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural, semisynthetic or synthetic wax or fat or fatty alcohol or fatty acid, or on a mixture of at least two of these afore mentioned components. 
     The water-insoluble polymers used to produce a sustained-release material are preferably based on an acrylic resin, which is preferably selected from the group of poly(meth)acrylates, particularly preferably poly(C 1-4 )alkyl(meth)acrylates, poly(C 1-4 dialkylamino(C 1-4 alkyl(meth)acrylates and/or copolymers or mixtures thereof, and very particularly preferably copolymers of ethyl acrylate and methyl methacrylate with a monomer molar ratio of 2:1 (Eudragit)NE30D®), copolymers of ethyl acrylate, methyl methacrylate and trimethylammonium ethyl methacrylate-chloride with a monomer molar ratio of 1:2:0.1 (Eudragit RS®), copolymers of ethyl acrylate, methyl methacrylate and trimethylammonium ethyl methacrylate-chloride with a monomer molar ratio of 1:2:0.2 (Eudragit RL®), or a mixture of at least two of the above-mentioned copolymers. These coating materials are commercially available as 30 wt. % aqueous latex dispersions, i.e. as Eudragit RS30D®, Eudragit NE30D® or Eudragit RL30D®, and may also be used as such for coating purposes. 
     In another embodiment, the sustained-release material is based on water-insoluble cellulose derivatives, preferably alkyl celluloses, particularly preferably ethyl cellulose, or cellulose esters, e.g. cellulose acetate. Aqueous ethyl cellulose dispersions are commercially available, for example, under the trademarks Aquacoat® or Surelease®. 
     As natural, semisynthetic or synthetic waxes, fats or fatty alcohols, the sustained-release material may be based on carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax, cetyl alcohol, cetylstearyl alcohol or a mixture of at least two of these components. 
     The afore mentioned polymers of the sustained-release material may also comprise a conventional, physiologically acceptable plasticizer in amounts known to those skilled in the art. 
     Examples of suitable plasticizers are lipophilic diesters of a C 6 -C 40  aliphatic or aromatic dicarboxylic acid and a C 1 -C 8  aliphatic alcohol, e.g. dibutyl phthalate, diethyl phthalate, dibutyl sebacate or diethyl sebacate, hydrophilic or lipophilic citric acid esters, e.g. triethyl citrate, tributyl citrate, acetyltributyl citrate or acetyltriethyl citrate, polyethylene glycols, propylene glycol, glycerol esters, e.g. triacetin, Myvacet® (acetylated mono- and diglycerides, C 23 H 44 O 5  to C 25 H 47 O 7 ), medium-chain triglycerides (Miglyol®), oleic acid or mixtures of at least two of said plasticizers. 
     Aqueous dispersions of Eudragit RS® and optionally Eudragit RL® preferably contain triethyl citrate. The sustained-release material may comprise one or more plasticisers in amounts of, for example, 5 to 50 wt. % based on the amount of polymer(s) used. 
     The sustained-release material may also contain other conventional auxiliary substances known to those skilled in the art, e.g. lubricants, coloured pigments or surfactants. 
     The pharmaceutical formulation of the present invention may also comprise at least one of the components (A) and (B) covered by an enteric coating form which dissolves as a function of pH. Because of this coating, part or all of the pharmaceutical formulation can pass through the stomach undissolved and the components (A) and/or (B) are only released in the intestinal tract. The enteric coating preferably dissolves at a pH of between 5 and 7.5. 
     The enteric coating may be based on any enteric material known to those skilled in the art, e.g. on methacrylic acid/methyl methacrylate copolymers with a monomer molar ratio of 1:1 (Eudragit L®), methacrylic acid/methyl methacrylate copolymers with a monomer molar ratio of 1:2 (Eudragit S®), methacrylic acid/ethyl acrylate copolymers with a monomer molar ratio of 1:1 (Eudragit L30D-55®), methacrylic acid/methyl acrylate/methyl methacrylate copolymers with a monomer molar ratio of 7:3:1 (Eudragit FS®), shellac, hydroxypropyl methyl cellulose acetate-succinates, cellulose acetate-phthalates or a mixture of at least two of these components, which can optionally also be used in combination with the above-mentioned water-insoluble poly(meth)acrylates, preferably in combination with Eudragit NE30D® and/or Eudragit RL® and/or Eudragit RS®. 
     The coatings of the pharmaceutical formulations of the present invention may be applied by the conventional processes known to those skilled in the art, e.g. from Johnson, J. L., “Pharmaceutical tablet coating”, Coatings Technology Handbook (Second Edition), Satas, D. and Tracton, A. A. (Eds), Marcel Dekker, Inc. New York, (2001), 863-866; Carstensen, T., “Coating Tablets in Advanced Pharmaceutical Solids”, Swarbrick, J. (Ed.), Marcel Dekker, Inc. New York (2001), 455-468; Leopold, C. S., “Coated dosage forms for colon-specific drug delivery”, Pharmaceutical Science &amp; Technology Today, 2(5), 197-204 (1999), Rhodes, C. T. and Porter, S. C., Coatings, in Encyclopedia of Controlled Drug Delivery. Mathiowitz, E. (Ed.), John Wiley &amp; Sons, Inc., New York (1999), Vol. 1, 299-311. The respective descriptions are incorporated by reference and are part of the disclosure. 
     In another embodiment, the pharmaceutical formulation of the present invention contains one or both of components (A) and (B) not only in sustained-release form, but also in non-sustained-release form. By combination with the immediately released form, a high initial dose can be achieved for the rapid onset of the beneficial effect. The slow release from the sustained-release form then prevents the beneficial effect from diminishing. Such a pharmaceutical formulation is particularly useful for the treatment of acute health problems. 
     This may be achieved, for example, by a pharmaceutical formulation having at least one immediate-release coating comprising at least one of the components (A) and (B) to provide for rapid onset of the beneficial effect after administration to the patient. 
     Administered dosages for acetylcholinesterase inhibitors and compounds with 5-HT 6  receptor affinity are in accordance with dosages and scheduling regimens practised by those of skill in the art. General guidance for appropriate dosages of all pharmacological agents used in the present methods is provided in Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 10 th  Ed., Hardman, Limbird and Goodman-Gilman, Eds., McGraw-Hill (2001) and in a Physicians&#39; Desk Reference (PDR), for instance, in the 57 th  or 58 th  Eds., Thomson PDR (2003 or 2004). Published dosages of acetylcholinesterase inhibitors and compounds for with 5-HT 6  receptor affinity are for indications distinct from treatment of obesity. Typically, efficacious dosages of acetylcholinesterase inhibitors and compounds with 5-HT 6  receptor affinity for practising the present invention can be equal to or less than (e.g., about 25, 50, 75 or 100%) the dosages published for other indications, such as for Alzheimer&#39;s disease and depression, respectively. 
     The present invention also relates to the treatment the aforementioned disorders and/or diseases with a combination of at least one compound with 5-HT 6  receptor affinity and at least one cholinesterase inhibitor which may be administered separately, therefore the invention also relates to combining separate pharmaceutical compositions into a kit form. The kit, according to this invention, comprises two separate pharmaceutical compositions: a first unit dosage form comprising a prophylactically or therapeutically effective amount of at least one cholinesterase inhibitor, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier or diluent in a first unit dosage form, and a second unit dosage form comprising a prophylactically or therapeutically effective amount of at least one compound with 5-HT 6  receptor affinity, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier or diluent in a second unit dosage form. The kit further comprises a container. Such kits are especially suited for the delivery of solid oral forms such as tablets or capsules. Such a kit preferably includes a number of unit dosages. Such kits can include a card having the dosages oriented in the order of their intended use. An example of such a kit is a “blister pack”. Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms. If desired, a memory aid can be provided, for example in the form of numbers, letters, or other markings or with a calendar insert, designating the days or time in the treatment schedule in which the dosages can be administered. 
     Examples 
     Pharmacological Methods: 
     I) Binding to Serotonin Receptor 5-HT 6    
     Cell membranes of HEK-293 cells expressing the 5HT 6 -human recombinant receptor were supplied by Receptor Biology. In said membranes the receptor concentration is 2.18 pmol/mg protein and the protein concentration is 9.17 mg/ml. The experimental protocol follows the method of B. L. Roth et al. [B. L. Roth, S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Y. Shen, H. Y. Meltzer, D. R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytryptamine-7 Receptors. The Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 1403] with the following slight changes. The respective part of the literature description is hereby incorporated by reference and forms part of the disclosure. 
     The commercial membrane is diluted (1:40 dilution) with the binding buffer: 50 mM Tris-HCl, 10 mM MgCl 2 , 0.5 mM EDTA (pH 7.4). The radioligand used is [ 3 H]-LSD at a concentration of 2.7 nM with a final volume of 200 μl. Incubation is initiated by adding 100 μl of membrane suspension, (≈22.9 μg membrane protein), and is prolonged for 60 minutes at a temperature of 37° C. The incubation is ended by fast filtration in a Brandel Cell Harvester through fiber glass filters made by Schleicher &amp; Schuell G F 3362 pretreated with a solution of polyethylenimine at 0.5%. The filters are washed three times with three milliliters of buffer Tris-HCl 50 mM pH 7.4. The filters are transferred to flasks and 5 ml of Ecoscint H liquid scintillation cocktail are added to each flask. The flasks are allowed to reach equilibrium for several hours before counting with a Wallac Winspectral 1414 scintillation counter. Non-specific binding is determined in the presence of 100 μM of serotonin. Tests were made in triplicate. The inhibition constants (K i , nM) were calculated by non-linear regression analysis using the program EBDA/LIGAND described in Munson and Rodbard, Analytical Biochemistry, 1980, 107, 220, the respective part of which is hereby incorporated by reference and forms part of the disclosure. 
     II) Behavioural Assessment of Cognitive Effects of Compounds with 5-HT 6  Receptor Affinity: Novel Object Discrimination (NOD) 
     Two separate groups of 12 adult male Lister hooded rats are tested in the NOD paradigm using 4 h inter-trial interval (ITI) delay between the familiarisation and choice trials which should ensure impaired discrimination and permit the pro-cognitive effects of the compounds to be evaluated. 
     In two separate groups of animals compound [1140] (6-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide) and donepezil HCl (or vehicle) were administered on four separate occasions, at seven day intervals. The semi-randomised design for drug administration ensures that for each group, each animal receives one of the four treatment combinations once during the study: compound [1140] and donepezil HCl, compound [1140] and vehicle, donepezil HCl and vehicle, vehicle and vehicle. Hence, each animal will serve as its own control within each group to minimise inter-individual variability. Drug pre-treatment occurred 20 min prior to the first NOD trial to ensure optimal drug plasma levels during acquisition and consolidation phases. 
     To maximise the opportunity to see a synergistic effect, the animals received one dose of donepezil HCl i.p. (0.05 mg/kg for group 1 and 0.1 mg/kg for group 2) in combination with the selected dose of compound [1140] (1 mg/kg) or the vehicle (saline containing 0.5 methylcellulose, 2 ml/kg). The synergism between compound [1140] and donepezil HCl was studied at both 0.05 and 0.1 mg/kg i.p. At the end of the study, seven days after the last drug administration all rats were given donepezil HCl at 0.3 mg/kg i.p. to confirm reversal of natural forgetting and hence the animals were tested in the NOD paradigm at five occasions. 
     The exact experimental protocol is outlined in detail in: 
     M. V. King et al, 5-HT6 receptor antagonist reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism, Neuropharmacology 2004, 47, 195-204 and Woolley et al. Reversal of cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790; Psychopharmacology 2003, 170, 358-367. 
     The respective parts of the literature are hereby incorporated by reference and form part of the present disclosure. 
     Pharmacological Data: 
     The behavioural assessment of cognitive effects of compounds with 5-HT 6  receptor affinity with the novel object discrimination (NOD) test was carried out as described above. 
     The results are depicted in  FIG. 1 . A denotes familiar and B denotes novel objects in this figure. 
       FIG. 1 . shows that the acetylcholinesterase inhibitor donepezil potentiates the action of the compound with 5-HT 6  receptor affinity, compound [1140]. Thus, the discrimination ratio is significantly greater when compound [1140] (1 mg/kg) is administered in combination with donepezil hydrochloride [compound [1140] (1 mg/kg)+donepezil hydrochloride(0.1 mg/kg)].  FIG. 1 . also shows that the combination of an amount of donepezil hydrochloride which does not have any effect in the NOD test by itself and an amount of compound [1140] which does not have any effect in the NOD test by itself can be combined to yield an active substance combination which shows a significant effect in the NOD test.